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8Abstract
Around 30 years ago, the discovery of modular protein domains began to change
the scientific world’s view on cell signalling. The multitude of ground-breaking
discoveries in this field over the past three decades increased fundamentally the
understanding of cellular signal transduction and how proteins transmit extra-
and intracellular signals in this context. The SH3 domain was one of the first
described modular protein domains and was soon found to be involved in
numerous important cellular functions and signalling cascades. Moreover, SH3
domain-mediated interactions were also found to be hijacked by pathogens,
especially viruses, which developed highly specific proteins mimicking cellular
SH3 domain ligands. This molecular mimicry allows the virus to interfere,
manipulate and exploit host cellular signalling for its own benefits and survival.
The vital elements of this doctoral thesis are the identification and
characterization of so far unknown, high-affinity SH3 domain-mediated
interactions and in the context of pathogenic SH3 domain ligand origin, also the
elucidation of functional consequences for the host cell. The first part describes
a large-scale screening approach uncovering high-affinity interactions between
human SH3 domains and potential native target proteins. The identified robust
SH3-mediated interactions are novel and thereby provide a valuable resource for
future research. The second part extends the focus to SH3-mediated interactions
between viruses and their host cells. These interactions are of exceptional
impact since they enable the virus to manipulate or hijack the host’s immune
defence system and thereby promote viral survival and propagation. Two
examples of viral proteins binding via an SH3-mediated interaction to host cell
factors are presented in this thesis: - the interaction of influenza A virus (IAV)
NS1 protein with host cell Crk-adaptor proteins in context of reorganizing the
Crk(L)-PI3 kinase signalling complex and  – the interaction between molluscum
contagiosum virus (MCV) MC159 protein and host cell SH3 binding protein 4
(SH3BP4). The study addressing the reorganization of the Crk(L)-PI3 kinase
signalling complex by NS1, focuses on structural and biochemical aspects of a
newly discovered trimeric protein complex and the related functional changes in
downstream signalling, such as Akt activation. The work presented on MC159
identifies host cell SH3BP4 as a new target protein of MCV and shows that the
SH3-mediated interaction between MC159 and SH3BP4 is essential for
suppression of cellular autophagy by MC159.
In summary, the work presented in this thesis highlights the fundamental
importance of SH3 domains in the cell and its crucial role in the exploration of
the host cell by viruses. By understanding cellular protein networks involving
9SH3-mediated interactions and viral strategies targeting the same, new potential
therapeutic targets can be identified, leading the way to novel or improved
treatments.
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Abbreviations
AAT amino acid transporters
Abl Abelson
AIDS acquired immunodeficiency syndrome
AP-2 activating protein2
BCR Breakpoint cluster region
CMA chaperon-mediated autophagy
CPSF30 cleavage and polyadenylation specificity factor 30
cRNA complementary RNA
Crk CT10 regulator of kinase
CrkL Crk-like
C-terminal carboxyterminal
DAP1 death-associated protein 1
DD death domain
DED death effector domain
DISC death-inducing signalling complex
DNA deoxyribonucleic acid
ED effector domain
EH Eps15-Homology
EspFU F-like protein encoded on prophage U
FGFR fibroblast growth factor receptor
FLIP FLICE (FADD-like interleukin-1 beta-converting enzyme,
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HA hemagglutinin
HIV-1 human immunodeficiency virus 1
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GRB2 Growth factor receptor-bound 2 protein
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1. Review of the literature
1.1. Introduction to protein interactions
Proteins are masterpieces of evolution. From the simplest forms of life to the
most complex organisms, nearly all biological processes depend on proteins and
their execution of biological information. Depending on their amino acid
sequence, structural features and function, proteins can be organized into
different families and superfamilies, in which each member has related, but not
identical functions. The architecture of most mammalian proteins resembles a
“building block system”, in which different, independently folded and organized
parts have distinct biochemical functions. These so-called "domains", either
carry out certain biochemical reactions or mediate physical proximity between
biological molecules. The principle of combining individual domains with distinct
functions in one protein allows high diversity in the landscape of protein
functions, as well as a high degree of regulation and control. Another advantage
of this combinatory concept is the thereby limited size of needed genetic
information, which is a favourable criterion for evolution  [1].
Also, protein domains have a fundamental function in the process of global
protein folding. By folding independently, they minimize possible interactions
between amino acids within the protein. Furthermore, the initial folding of
individual domains buries aggregation-prone hydrophobic amino acid residues
in the core, while exposing hydrophilic residues [2, 3].
Complex cellular reactions and signalling cascades are carried out by
multiprotein complexes and protein networks, respectively. Regarding the
former, the presence of individual protein domains promotes higher degrees of
stability for multiprotein complexes while reducing the likelihood of
opportunistic interactions. For the latter, the combination of protein domains in
the signalling cascade members determines the cascade’s assembly in terms of
localization, direction as wells as control [1].
Detailed information on the protein structure facilitates understanding the
biological function and importance of a protein. However, obtaining structural
information by, e.g. nuclear magnetic resonance (NMR) or X-ray crystallography
from full-length proteins is often challenging. In contrast, obtaining the
information from isolated domains is mostly successful, allowing conclusions on
the overall protein structure by solving the structure of individual protein
domains.
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For understanding the role of a protein plays in a cellular process, it is essential
to identify and characterize its interacting partners and cellular environment. For
this purpose, yeast-two-hybrid screens (Y2H), protein-arrays, and phage display
screenings are most commonly used [1].
1.2. Phage display
“Phage display is one of the oldest and most powerful combinatorial biology
methods” [4]. By fusing a polypeptide to the coat proteins of a bacteriophage
(e.g. p3 or p8 of M13), it is possible to display the former in its native form. The
DNA-encoded genetic information of the displayed polypeptide is located on a
phagemid, which allows the generation of enormously large polypeptide
libraries (>1011) using basic molecular biological methods. Phages are optimal
tools for displaying this type of libraries, since they are produced quickly in very
high numbers and can easily be concentrated into small volumes. The protein of
interest is usually immobilized when presented to the phage library (so-called
“panning”), what allows easy access to the enriched phage population/s, which
is/ are present if an interaction takes place between the protein of interest and
the displayed polypeptide. Since every bacteriophage contains the DNA-
sequence of the displayed polypeptide, it is possible to identify enriched clones
by standard Sanger-sequencing [4]. Polypeptides displayed by the
bacteriophages can be ligands for protein modules or the protein modules
themselves when using the reverse approach. For identification of protein
domain interacting partners applies the same principle of either displaying the
domain ligand or the domain itself. The SH3 and WW (tryptophan-tryptophan)
domain, but also single-domain antibody libraries are examples of domains that
have been successfully expressed in and displayed on bacteriophages [1].
Figure 1. SH3 domain-displaying bacteriophage.
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1.3. SH3 domains
SH3 domains are prototypes of modular protein domains. In eukaryotic genes
the SH3 domain is one of the most abundant modular domain, indicating its
essential role for the cell. The human genome encodes approximately 300 SH3
domains present in approximately 220 different human proteins [5]. Several SH3
domains can be found in a single protein. For example, the scaffold protein Tuba
contains six SH3 domains and thus, represents the protein containing the highest
number of individual SH3 domains found in one single polypeptide [6]. In
average, SH3 domains comprise of 60 amino acids,  which fold into a compact
beta-sandwich, which consists of five major beta-strands. The first three major
strands are connected by three loops, namely RT-loop, N-Src-loop and the distal
loop, whereas a 310helix separates the last two strands [7].
1.3.1. Ligands and mode of interaction
Ligands capable of binding to SH3 domains are mainly peptides which can adopt
the conformation of a left-handed polyproline-2 helix (PPII2). As the name
indicates, prolines are likely to form this type of helix, which is why SH3 ligands
often contain prolines in high frequency. The so-called “hydrophobic groove” of
the SH3 domain represents the binding region for these ligands, it
accommodates  several  conserved aromatic  residues  and is  flanked by  the RT-
and N-Src-loop [8]. The affinity and specificity of proline-rich peptides that bind
to SH3 domains are mostly moderate- usually with a KD in the micromolar range,
indicating a transient and dynamic mode of interaction. The necessity of this
transient interaction character becomes apparent when considering that SH3
domains frequently function as adaptors in highly dynamic cell signalling
cascades. Nevertheless, SH3-mediated interactions can also be highly specific
and show high affinities in the low nanomolar range. This is mainly accomplished
by additional interaction surfaces on the SH3 domain or the ligand, contacts
between other domains of the two interaction partners or the interplay between
additional members of a multiprotein complex [9].
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Figure 2. Binding of class I and II ligands to the SH3 domain. Both motifs, class I and II, adopt
a PPII2-helix conformation. The essential prolines (dark yellow) and positive amino acids (light
blue) of the ligands interact with the hydrophobic groove (grey rhombus) and the specificity
pocket of the SH3 domain, respectively. Modified after [7].
1.3.1.1. Typical and atypical binding motifs
The first identified minimal consensus sequence of SH3 ligands is the nowadays
commonly known PxxP motif, where “P” represents proline and, “x” stands for
any amino acid. The hydrophobic groove of the SH3 domain contains two distinct
xP-binding pockets positioning the ligand on the SH3 domain interacting surface.
This positioning can happen in two different orientations- depending on the N-
or C-terminal location of a positively charged residue, relative to the PxxP motif
[7]. The positively charged residue interacts with a negatively charged region of
the SH3 domain, the “specificity pocket” [10, 11]. Depending on the ligand’s
orientation relative to the SH3 domain binding site, it is classified either as class
I ligand (consensus sequence +xxPxxP, where “+” is a positively charged amino
acid) or class II ligand (consensus sequence PxxPx+)[9]. Both consensus
sequences are understood as “typical binding motifs”, in other words, canonical
motifs fitting the binding pockets of the SH3 domain interaction surface.
Whereas  most  of  the  identified  SH3-ligands  define  as  class  I  or  II  ligand,  a
considerable number of SH3 binding partners cannot be grouped into either of
the classes, due to their lack of the typical binding motif. Consequently, these so-
called "non-consensus ligands” [9, 12] or “atypical motif” containing ligands do
not necessarily adopt the PPII-helical conformation or interact with the binding
pockets of the SH3 domain hydrophobic groove. Instead, the interaction is often
mediated via the “specificity zone”, an area of the SH3 domain surface (including
the specificity pocket), which engages with the ligands via extended atomic
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contacts. Interestingly, this mode of SH3 domain interaction can result in a
remarkably increased affinity and specificity and can outperform the xP-binding
pocket in terms of contribution to the overall affinity and selectivity of the
interaction [9].
1.3.2. Cellular functions of SH3 domains
SH3 domains are involved in numerous cellular functions. As an integral part of
Src-family phosphotyrosine kinases (PTKs), they take part in the regulation of cell
proliferation and modification, cell migration, modification of components of the
cytoskeleton and cell survival signalling cascades. Substrate recognition and
regulation of PTK activity are the main mechanistic functions of SH3 domains in
this context [13]. Many SH3 domain-containing proteins, which do not belong to
the family of PTKs, are functioning as adaptor molecules in the cell. By binding to
their ligand and translocating it to another site or compartment of the cell, for
example to the cell membrane (where the input signal originates from a receptor
tyrosine kinase [RTK]), the ligand-protein gets into proximity with its substrate
or another interaction partner. A well-known example for this scenario is the
binding of Growth factor receptor-bound 2 protein (GRB2) SH3 domain to Son of
sevenless (Sos) and their translocation to the cell membrane via the interaction
of GRB2 SH2 domain with the phosphorylated and thereby active RTK. The
increased concentration of Sos at the cell membrane allows the interaction and
consequently, the activation of the small G protein Rat sarcoma (RAS) [5].
Adapter molecules which contain several modular domains in addition to an SH3
domain can also function as scaffolding proteins for protein assembly [13].
1.3.3. Diseases involving dysregulation of SH3 domain-mediated interactions
Due to the involvement of SH3 domains in a multitude of cellular functions and
signalling pathways, the dysregulation or alteration of SH3-mediated
interactions can lead to various pathologies, including cancer. A crucial example
of altered SH3 domain-mediated interactions contributing to abnormal cell
signalling and potentially resulting in cancer, is the loss of the autoinhibitory
function of Abelson (Abl)-SH3 domain in Breakpoint cluster region (BCR)-Abl.
Normally engaged in an intramolecular interaction with a proline residue
(located between the Abl SH2 and catalytic domain), the SH3 domain contributes
to a limited catalytic activity of Abl. Mutations either in the SH3 domain or in its
intramolecular contact region can thereby result in a loss of this critical
regulatory inhibition of Abl-kinase activity [14, 15]. The ”Disintegrin and
metalloproteinase domain-containing protein 15” Adam15 was found to be
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associated with prostate and breast cancer progression. Interestingly, Adam15
exists due to alternative splicing, in different isoforms in the cell. Those isoforms
contain different sets of proline-rich motifs and bind consequently to different
SH3 domain-containing proteins or, like the isoform 1, do not support SH3-
mediated interactions at all [16]. The dysregulation of alternative splicing of
Adam15 can alter the interaction profile of the protein dramatically and
contributes to the development of cancer [17].
1.3.4. SH3 domains employed by pathogens
Considering the ubiquitous occurrence of SH3 domains in the cellular protein
landscape and their importance in cellular signalling and physiology, it is
apparent why pathogens adopted this domain from their hosts [18] or developed
ligands, which can bind cellular SH3 domains by incorporating so-called “short
linear binding motifs”[19], into their proteins [20]. The most prominent
examples of pathogen-acquired SH3 domains are v-Src, a viral oncogene
identified from the avian Rous sarcoma virus [21] and v-Crk, likewise a viral
oncogene, but originated from avian CT10 virus [22]. Both viral proteins
transform and promote tumour development in chickens [18]. V-Src is a
constitutively active tyrosine kinase, constantly triggering cellular signalling
pathways, what consequently leads to cancer development [23]. V-Crk, initially
named “p47gag-crk” [24] is a fusion of the viral gag-protein and the “CT10 regulator
of kinase” aka Crk. Later, the viral fusion protein was identified as being
structurally identical to the SH2- and SH3 domain of cellular Crk, indicating its
host cellular origin [25].
1.3.4.1. Viral SH3 domain ligands
Instead of acquiring and employing an entire SH3 domain, many pathogens, in
fact mostly viruses, express ligands capable of binding to cellular SH3 domains.
This so-called “molecular mimicry”[26] allows pathogens effectively to interfere
with or hijack host cellular functions and signalling mechanisms. One prominent
representative is the HIV-1 Nef protein, which was found to bind cellular Hck and
thereby promoting viral replication in vitro [27].  The  Hepatitis  C  virus  NS5a
protein is described to inhibit Bin-1 induced apoptosis by establishing a direct
interaction with Bin-1 [28]. Further examples are the promotion of Alphavirus
replication by the interaction of viral nsP3 proteins and cellular Amphiphysins
[29], the inhibition of the Raf/ MAPK signalling pathway by HIV-1 Tat binding to
Grb2 [30] and others [31]. The binding of Escherichia coli-secreted protein F-like
protein encoded on prophage U (EspFU) to insulin receptor tyrosine kinase
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substrate (IRTKS) SH3 domain, is one example of bacterial proteins functioning
as ligands for host cellular SH3 domains. This interaction is special, since due to
the occurrence of tandem PxxP motifs in EspFU, it  is  one  the  most  affine  SH3
domain interactions found in nature. A consequence of this interaction is the
modulation of the cellular actin assembly machinery by E.coli [32]. An example
of particular interest for this doctoral thesis was reported by Heikkinen and
colleagues, who discovered the binding of avian and Spanish Influenza A virus
NS1 protein to cellular Crk(L) proteins, which was found to increase the
activation of PI3kinase signalling [33].
1.4. Influenza A virus (IAV)
The host range of IAV is remarkably wide. It was isolated from humans, domestic
animals like cats, dogs, pigs and horses, from marine mammals as well as wild
and domestic birds like ducks, geese, gulls or terns. However, wild birds are
believed to serve as the primary natural reservoir of the virus.  Transmissions of
IAV from wild birds to mammals are not frequent, yet they are repeatedly
observed. Furthermore, the transmitted reservoir strains can persist and
circulate in their new host [34].
1.4.1. Disease and epidemiology
Worldwide, IAV is one of the most common causative agents of respiratory
infections. An infection with IAV typically leads to a sudden onset of high fever,
pain in the muscles, headache, a severe feeling of illness and fatigue, but also to
sore throat, cough and coryza [35]. Due to its morbidity and the high number of
fatalities, IAV poses a substantial burden to global health. The number of deaths,
which yearly account to the so-called “seasonal flu” range between 250000 to
500000 [36]. It is assumed, that large outbreaks of IAV, so-called “pandemics”,
recurrently happen since the middle ages. Already Hippocrates described a
disease with influenza-like symptoms in 412 BC. However, scientists still dispute
whether the described symptoms fit better a diphtheria diagnosis [37].
Nevertheless, after 1580, when the first commonly agreed IAV pandemic
occurred, numerous pandemics have taken place, costing millions of lives
throughout the centuries. The probably most famous and fatal pandemic was
the  so-called  “Spanish  flu”  from  1918,  which  alone  caused  an  estimate  of  50
million deaths worldwide [38]
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1.4.2. Classification, viral architecture and life cycle
Influenza A viruses represent one of seven genera of the Orthomyxoviridae
family. As typical for orthomyxoviruses, the genome of IAV consists of negative
single-strand RNA segments, which are bound to viral nucleoproteins (NP) [34].
The total genome size is estimated to be about 14 kb [39]. The definition of IAV
subtypes bases on the viral surface glycoproteins hemagglutinin (HA) and
neuraminidase (NA), whereas 16 different HA and nine different NA
glycoproteins exist. Interestingly, human epidemics have been caused by only
three of the 16 HA types- HA1, -2, and -3 and two types of NA- NA1 and –2. Under
the electron microscope, IAV shows a spherical or filamentous shape. The
filamentous form often exceeds 300 nm in length, whereas the diameter of the
spherical form is about 100 nm. A host cell-derived lipid bilayer surrounds the
virion and is spiked with the HA and NA glycoproteins. In addition, Matrix 2 (M2)
ion channels cross the viral membrane. Notably, the number of M2 channels
embedded  in  the  membrane  is  with  an  M2  to  HA  ratio  of  1:10  to  1:100
comparably small. Beneath the membrane, a matrix consisting of M1 protein
surrounds the viral core. This inner part of IAV contains the ribonucleoprotein
complexes (RNP) which are RNA segments wrapped around NP, along with the
RNA-dependent RNA-polymerase heterotrimer (consisting of the subunits PB1,
PB2 and PA) and the nuclear export protein (NEP or non-structural protein (NS
2)[34].
Figure 3. Transmission electron microscope (TEM) image and schematic depiction of an IAV.
TEM Credits: CDC/ Dr. Erskine. L. Palmer; Dr. M. L. Martin
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To infect the host cell, IAV binds to sialic acid-containing cell surface receptors
and enters the cell via endocytosis. In the next step, the viral and endosomal
membranes fuse what causes the RNPs to liberate into the cytoplasm.
Subsequently, the RNPs are transported to the nucleus, where the viral RNA-
dependent RNA-polymerase transcribes the negative-strand viral RNA (vRNA)
into positive-strand complementary cRNAs, which serve as templates for vRNA
production. The same viral RNA-polymerase also transcribes the vRNA into 5’
capped and 3’ polyadenylated mRNA, which allows the viral mRNA to be
exported and translated by host cell mechanisms. The assembly of new virions
happens at the host cell membrane, where newly assembled vRNPs (which are
first exported from the nucleus) are, along with the M1 protein, the NEP, and
NS1 protein, included in the budding IAV progeny [40].
1.4.3. Genome organization
As mentioned above, the genome of IAV consists of eight single-stranded,
negative-sense viral RNA segments. The numerical annotation of the segments
follows their size in kb, starting with the largest segment. Table 1 illustrates the
eight segments, their translated proteins and protein functions. The segments 7
and 8 are the only ones from which more than one protein is generated by
alternative splicing. Table 1 shows the ten essential viral proteins (highlighted in
bold), which are translated from the eight IAV RNA segments. Additionally, two
proteins are listed, which are expressed from the PB1-segment by alternative
start codon usage: PB1-frame 2 (PB1-F2) and PB1-N40 protein. The existence of
other accessory proteins,  like PA-N182, PA-N155, PA-X, PB2-S1, M42 or NS3 is
strain-dependent [41].
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Table 1. Genome segments encoded by IAV and their corresponding proteins and functions.
Proteins in bold letter represent essential viral proteins, modified after [30].
The segmented genome of IAV allows the so-called phenomenon of “antigenic
shift”, which can pose a severe threat to the human population by potentially
causing new pandemics. The term “antigenic shift” describes a significant change
in the hemagglutinin structure of an IAV newly introduced to humans, compared
to HA structures already known to the human immune system. This can happen
via two different mechanisms- either by the direct transmission of an unknown
IAV strain from non-human species to humans or by reassortment events
between different IAV strains simultaneously infecting one host cell, resulting in
a new IAV strain [42].
Segment length in
nucleotides
Protein/s length in
amino
acids
Protein function
1 2341 Basic polymerase
protein 2 (PB2)
759 Polymerase subunit, mRNA cap-
binding
2 2341 Basic polymerase
protein 1 (PB1)
PB1-N40
PB1-frame 2 (PB1-F2)
757
718
87
Polymerase subunit, elongation of
RNA and viral RNA synthesis,
endonuclease function
Unknown
Function in apoptosis activation
3 2233 Acidic polymerase
protein (PA)
716 Polymerase subunit with proteolytic
activity
4 1778 Hemagglutinin (HA) 550 Surface glycoprotein, mediates
binding to the receptor and fusion,
major antigen
5 1565 Nucleoprotein (NP) 498 RNP component, regulates nuclear
import
6 1413 Neuraminidase (NA) 454 Surface glycoprotein, sialidase
activity, release of the virus
7 1027 Matrix protein 1
(M1)
Matrix protein 2
(M2)
252
97
Matrix protein, interacts with the
RNP, involved in regulation of
nuclear  export  of  RNA  and  in  viral
budding
Ion channel, involved in uncoating of
the virus and its assembly
8 890 Nonstructural
protein 1 (NS1)
Nonstructural
protein 2 (NS2/ NEP)
230
121
Multifunctional host cell defence
antagonist
Nuclear export protein
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1.4.4. Non-structural protein 1 (NS1)
Segment 8, which is the smallest RNA segment of IAV, encodes via alternative
splicing for two proteins- the NS1 protein and the nuclear export protein (NEP).
NS1 is considered the primary host cell immune response antagonist, with an
essential role in suppressing the IFN-α/ β primed antiviral state of the host cell.
However, the functions of NS1 are manifold [43].
1.4.4.1. Structural composition
The length of the NS1 protein is IAV strain-specific and varies between 230 and
237 amino acids. Nevertheless, the majority of IAV strains encode an NS1 protein
of 230 amino acids, resulting in a polypeptide with a molecular weight of around
26 kDa. NS1 divides into two functional domains, the RNA-binding domain (RBD,
amino acids 1-73), located at the N-terminus and the C-terminal effector domain
(ED,  amino  acids  85-230/7)  where  the  last  30  amino  acids  form  a  so-called
“disordered tail”. Both domains are separated by a short flexible linker region,
whose sequence can vary substantially among different IAV strains. Also, the
disordered tail shows significant differences in amino acid composition
depending on the IAV strain. The variability of the linker and the disordered tail
contribute substantially to the strain-specific functions of NS1 [44].
As the name implies, the RBD binds different RNA species, whereas no sequence
specificity exists. A requirement for RNA binding is, however, the
homodimerization of two NS1 molecules. In the full-length protein, dimerization
is supported by both, the RBD and effector domain. It has been shown, though
that the RBD and ED can also independently dimerize [43]. Apart from stabilizing
the homodimerization, the main function of the NS1 ED is mediating interactions
with host cell proteins.
1.4.4.2. Functions of NS1 in the viral life cycle
A major role of NS1 is counteracting the host cell interferon (IFN) production and
thereby suppressing one of the most important innate immune defence
mechanisms of the host cell. Upon pathogen invasion, viral RNA is recognized by
pattern recognition receptors (PRRs) as foreign, what initiates the production of
Type I IFNs (IFN-α/ β), as a first measure of the cell containing progression and
spread of the infection [45]. These soluble cytokines act by upregulating the
expression of more than 300 IFN-stimulated antiviral genes (ISGs). This gene
upregulation takes place inside the cells from which the cytokines are secreted
(autocrine), but also in neighbouring cells (paracrine)[46]. NS1 proteins utilize
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two different mechanisms to interfere with the IFN signalling, whereas it is
important to note, that not all NS1 proteins are capable of executing these two
mechanisms similarly. The first mechanism is the so-called “pre-transcriptional
limitation of IFN-β induction” [43], where NS1 targets the Tripartite motif-
containing protein 25 (TRIM25) ubiquitin ligase, which is essential for retinoic
acid-inducible gene I (RIG-I) and downstream IFN activation. The second
mechanism or “post-transcriptional limitation of IFN-β induction” [43], happens
by binding of NS1 to the cellular cleavage and polyadenylation specificity factor
30 (CPSF30). This interaction inhibits the processing of all cell host pre-mRNA by
CPSF30 and subsequently their translation and expression. This also includes the
expression of IFN-β and all ISGs [47]. Another way how NS1 antagonizes the host
innate immune response is by interfering with the function of the 2ʹ-5ʹ-
oligoadenylate synthetase (OAS) and the dsRNA-dependent serine/threonine
protein kinase R (PKR), which are two cytoplasmic proteins promoting antiviral
activities of the host cell. While the inhibitory action of NS1 on PKR is the result
of a direct interaction between the two proteins [48, 49], the effect of NS1 on
OAS is believed to be indirect, possibly by outcompeting OAS over dsRNA binding
[48]. Further, NS1 has been found to induce the phosphorylation and subsequent
inhibition of c-Jun N-terminal kinase (JNK). This leads to downstream inhibition
of the transcription factors ATF-2 and c-Jun and subsequently to the suppression
of IFN-β gene expression [50].
Apart from hampering the IFN production, NS1 is interfering with a plethora of
other host cellular pathways by interacting with a large number of host cell
proteins. One example is the interaction of avian NS1 with PDZ domain-
containing proteins, like Scribble and Dlg-1, via a C-terminally located PDZ
binding motif. The interaction of NS1 with Scribble was found to protect the IAV
infected cells from proapoptotic actions of Scribble [51]. Additionally, both PDZ
domain-mediated interactions were found to abrogate cellular tight junctions
and thereby increase permeability in IAV infected cells [52]. Another interaction
of NS1 with a significant impact on host cell signalling is the one with the
regulatory phosphatidyl-inositol-3 kinase (PI3K) subunit p85β. By binding to the
inter SH2-domain of p85β, NS1 releases inhibitory contacts between p85β and
p110, what results in the activation of PI3K/Akt signalling [53, 54]. With Akt
having over more than 100 protein substrates, the PI3K/Akt signalling pathway
has an impact on numerous cellular functions, like apoptosis, proliferation, and
cytokine production. [43].
25
1.4.4.3. NS1 as SH3 domain ligand and interaction with Crk adaptor proteins
In 2008 Heikkinen and colleagues [33] identified a perfect class II SH3-binding
motif in NS1 proteins from avian IAV strains, which is absent in nearly all human
IAV strains. Only four human isolates were found to contain the C-terminally
located SH3 domain binding motif, and strikingly, three of these four isolates
were zoonotic transmissions. Among them the IAV strain of the highly fatal
Spanish flu from 1918 (A/Brevig Mission/1/18/H1N1). Using a phage library
displaying a virtually complete collection of 296 human SH3 domains, the N-
terminal SH3 domains of CrkII and CrkL could be identified as preferred binders
of the NS1 SH3 binding motif. The same study also showed the interaction of NS1
with all full-length Crk proteins from transfected and infected cells. The Crk-
family proteins CrkI/II and CrkL represent a special class of regulatory proteins,
called adaptor proteins. Their study provided great insight into the
understanding of how “modular protein modules assemble into organized
protein-protein networks during signal transduction” [48]. Crk adaptor proteins
have an integral role in tyrosine kinase signalling, and thereby integrate signals
from different origins, e.g. growth factors, extracellular matrix proteins,
apoptotic cells and pathogens. There is striking evidence that alterations of
Crk(L) functions lead to pathologies, including cancer and pathogen susceptibility
[55].
1.4.4.4. Alteration of host cell PI3-Kinase (PI3K) signalling by NS1-Crk
interaction
In addition to the NS1-Crk(L) interaction, Heikkinen and colleagues also identified
the functional consequence of this assembly. After analysing the activation
status of PI3K by quantifying phosphorylated Akt signals from Western blotting
experiments (pAkt, Ser473), a significant increase in pAkt levels could be
observed when Crk(L) binding competent NS1 proteins were transfected. In
contrast, NS1 proteins incapable of binding to Crk(L) caused only a modest
increase in PI3K activity [33]. Interestingly, Crk(L) proteins have been previously
indicated in PI3K signalling. Reports from Sattler [56] and Gelkop [57] show a
direct association of CrkL and CrkII, respectively, with p85, where the binding
occurs via a proline-rich motif in p85 and the N-terminal SH3 domain of the Crk
proteins. In both studies, the CrkII/L-p85 complex involved a third protein- the
Casitas B-lineage Lymphoma E3 ubiquitin-protein ligase (Cbl). The complex plays
a role in PI3K signalling upon immune cell activation [57] and signalling in chronic
myeloid leukaemia [56].
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1.5. Molluscum contagiosum virus
Since  the  eradication  of  smallpox  in  1980,  MCV  is  the  only  member  of  the
Poxviridae family, commonly establishing infections in humans. The natural
reservoir for MCV are humans, whereas diseases resembling an MCV infection
have been reported in several other hosts like birds and other mammalian
species [58]. A report from Fox and colleagues [59] stated an MCV-like infection
in two donkeys. The authors could identify the causative agent as most likely
belonging to the Molluscipoxvirus genus (in which MCV is so far the only
member). However, none of the isolates could be proven to be an MCV subtype,
leaving the known MCV strains restricted to humans. The natural reservoir of
MCV is not the only defining feature when comparing it to other poxviruses.
Unlike, e.g. variola virus (VAR, the causative agent of smallpox) which
systemically infects the human body, the replication of MCV is restricted to the
human epidermis. There, MCV causes generally only localized and subacute
infections. Remarkably, the virus does not cross the epidermal basement
membrane of the stratum basale and remains thereby almost invisible to the
host cell immune system [60].
1.5.1. Disease and epidemiology
MCV infection can be mainly seen in children (usually 2 to 5 years old), young
adults and immunocompromised individuals. A hallmark of the infection is the
presentation of defined, glossy, skin-coloured lesions, which have a dome-
shaped, umbilicated appearance. The disease can be transmitted directly via skin
to skin contact or by sexual contact, whereas the latter leads to an infection of
the genital area. Indirect transmission via objects has also been reported [60].
Further, MCV is also considered to be transmitted vertically from mother to child,
since several cases of congenital MCV infections are described [61, 62]. The
progression and severity of MCV infection can vary dramatically, depending on
the immunocompetence status of the infected individual. In healthy,
immunocompetent patients, MCV is usually  benign and self-limiting. The lesions
also called “Mollusca” range from 3 to 5 mm in size. The average duration of
infection is 6 to 12 months, although cases have been reported where the
infection lasted up to 4 years [63]. This long-lasting persistence of the virus is a
consequence of the versatile repertoire of MCV immune evasion strategies [64].
The lesions themselves do not itch, yet, often a localized eczematous dermatitis
can be found surrounding the lesions, what causes the sensation of itching to the
patients. A frequent consequence is an irritation, secondary bacterial infection
and inflammation of the Mollusca, what promotes the further spread of the virus
over the skin and causes significant discomfort to the (often very young) patients
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[60]. The clinical picture of MCV infection in immunocompromised patients is
generally more severe than in humans with a fully functional immune system.
Lesions are larger- typically 10- 15mm, therefore the disease is also referred to
as “giant molluscum contagiosum”. Furthermore, the number of lesions is highly
increased, and they cover large areas of the patient’s skin, including face, neck
and scalp [65]. Since the lesions increase in size and number with the progression
of immunodeficiency, severe and challenging to treat MCV is often seen in HIV-
positive patients with late stages of AIDS and is also recognized as typical
comorbidity of the disease [63].
The clinical management of MCV includes physical therapies such as curettage
or cryotherapy, the application of chemical agents- e.g. Trichloroacetic acid
100%, Phenol 10%, Cantharidin 0.9% (and others), the treatment with immune
modulators like Imiquimod 5% cream or the use of antiviral agents as Cidofovir
(either topical or in very severe cases intravenously) [60].
1.5.2. Classification and characteristics
Belonging to the family of Poxviridae, MCV is to date the only known member of
the Molluscipox genus, comprising four known subtypes- MCV-1, 2, 3 and 4.
MCV-1 accounts,  with  98% of  all  cases,  for  most  childhood infections.  In  HIV-
positive patients, MCV-2 is the most commonly seen subtype. Geographical
differences in subtype distributions can also be seen, with MCV-3 and MCV-4
being mainly detected in Asia and Australia [63]. Alike other known poxviruses,
the genetic information of MCV is encoded on a linear DNA double-strand. The
total genome is about 190 kb in size and shows a high content of guanine and
cytosine bases- 63%, which is twice as much as the vaccinia virus contains [60].
The viral genome is enclosed in a, for poxviruses typical, dumbbell-shaped
protein core, which itself is surrounded by a post-Golgi-derived lipoprotein
envelope [64]. The replication of MCV takes place in the cytoplasm of the
infected host cell. For that purpose, the virus utilizes a DNA-dependent RNA
polymerase, which is included in the virion. Newly assembled viral cores occur
initially in the basal epidermal layer of the skin. A hallmark of MCV infection, the
viral inclusion bodies also called “Henderson-Paterson bodies” or “molluscum
bodies”, appear three to four layers above the basal layer of the epidermis.
Recognized as the site in the host cell cytoplasm where the virus is assembled,
the “Henderson-Paterson bodies” increase in size, the closer they move towards
the granular cell layer. A consequence of the increasing viral inclusion bodies size
is the displacement of the host cell nucleus and other organelles. At the final
stage of MCV inclusion body maturation, the stratum corneum ruptures and
releases a high number of infectious viral particles [60].
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 Figure 4. Progression of MCV maturation. Adapted from [53].
1.5.3. Genetic features of MCV
In 1996, the first complete sequence of an MCV genome became available and
based on this sequence, 163 proteins were initially predicted, of which 104 were
reported to be homologous to vaccinia virus (VV) or VAR proteins [66]. One year
later, the number of predicted proteins was corrected to 182 and 105 VV/ VAR
homologous proteins [67]. Despite the similarities in the phylogenetic tree of the
Poxviridae family, MCV is located more closely to parapoxviruses (e.g. Orf virus)
than to orthopoxviruses (e.g. VV and VAR) [68]
Like in many other poxviruses, most of the conserved poxvirus genes can also in
MCV be found in the central part of its genome. The genes which are exclusive
for MCV, are encoded in the flanking region of the viral genome [60]. Since MCV
infection is restricted to human keratinocytes, it is most likely that the proteins
encoded by MCV-specific genes play a role in virus-host cell interactions. This
also includes the versatile immune evasion strategies, which the virus executes
via its extensive set of immunomodulatory proteins [64].
1.5.4.  MC159 protein
A key player in immune evasion of the host cell by MCV is the MC159 protein.
Notably, 77 of the 182 genes of MCV have presumably immunomodulatory
functions and only six proteins have been studied in more detail. Remarkably, of
those six MCV proteins, MC159 and its close relative MC160 have until this day
probably drawn the most scientific attention [64]. Both proteins belong to the
so-called FLIP ((FLICE (FADD-like interleukin-1 beta-converting enzyme, aka
caspase-8)-inhibitory proteins) family. This important protein family consists of
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cellular and viral proteins which regulate cellular apoptosis at the site of the
death-inducing signalling complex (DISC) by interacting either with FADD (Fas-
associated protein with death domain), Caspase-8 or both [69]. Further, FLIPs
have been found to play a crucial role in the regulation of NF-κB and interferon
regulatory factor 3 (IRF3) activation [70]. Moreover, Lee and colleagues showed
in their work an inhibitory effect of FLIPs on autophagy [71].
Figure 5. FLIP protein family. In grey: death effector domain (DED); in yellow: caspase domain;
in green: caspase-like domain; in orange: α0-helix containing partly PxxP-motif, only present
in the DED1 of MC159; white: regions without domain structure adapted from [57]
1.5.4.1. Structural composition
As a member of the FLIP protein family, the 25kDa MC159 contains two tandem
death effector domains (DED1 and DED2) which span from position 8 to 175 of
the total 241 amino acids (aa) of the protein [64]. Both DEDs of MC159 are clearly
distinct from each other in sequence and structure. Furthermore, the DED1 (aa
8-78) differs not only from the neighbouring DED2, also compared to other
known DEDs (e.g. FADD DED), it has unique topological features. While DEDs
typically comprise six α-helices, the DED1 of MC159 has two additional α-helices-
helix H0, located at the very N-terminus and helix H7 and the end of DED1.
Furthermore,  helix  H2  is  shorter,  and  helix  H3  is  missing  in  MC159  DED1.
Importantly, the crystal structure of MC159 aa 1-187 unveiled a tight association
between DED1 and DED2, resulting in a compact, dumbbell-shaped overall
structure. The 54 aa long C-terminal tail of MC159 was found to be disordered in
the crystal [72], which indicates high flexibility of this region. Thurau and
colleagues identified two tumour necrosis factor (TNF) receptor (TNFR)
associated factor (TRAF) 3- binding sites in the C-terminal region of MC159 [73]
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1.5.4.2. Immunomodulatory functions of MC159
1.5.4.2.1.MC159 and apoptosis
The structural features, defining MC159 as FLIP, implicated early a role of MC159
in death receptor-mediated apoptosis and DISC formation. However, at this
moment it was not clear, whether MC159 FLIP has pro- or anti-apoptotic
activities. The ability of MC159 to inhibit TNFR- and Fas-induced apoptosis was
following the first discovered function of the viral protein [74, 75]. Both DEDs of
MC159 are essential for this function and cannot be interchanged or replaced by
closely related DEDs [76]. Also, two RxDL motifs located at the C-terminal end of
each  MC159  DED  are  crucial  for  its  anti-apoptotic  properties  [77]  Both  TRAF
binding sites reportedly have a supportive function for the anti-apoptotic activity
of MC159 [73]. Several studies addressed the question of how MC159 impairs
DISC assembly and thereby prevents death receptor-induced apoptotic signalling
[72, 76-78]. Recent work by Fu and colleagues [79] revealed the mechanism by
acquiring Cryo-EM structures of Caspase-8 tandem DED filaments, also in the
presence of MC159. The so revealed mechanism of MC159 interference with
DISC assembly was surprising due to its novel and unique nature. MC159
interacts via its DEDs with FADD and Caspase-8 DEDs and prevents the pro-
apoptotic nucleation and polymerization of caspase-8 at the DISC, a mechanism
which was named “capping” [79].
1.5.4.2.2.MC159 and the inhibition of TNF-mediated NF-κB activation
Another essential immune modulatory function of MC159 is the protein’s ability
to inhibit TNF-induced activation of nuclear factor 'kappa-light-chain-enhancer'
of activated B-cells (NF-κB) [81, 82]. Counteraction of NF-κB signalling is in the
case of MCV contributing to viral survival since active signalling of this pathway
leads to the expression of genes involved in pro-inflammatory and immune
responses [83]. Randall and colleagues found that MC159 is interacting with the
IκB kinase (IKK) complex [80], which is the master regulator of NF-κB signalling
[84].  The  same  study  concluded  that  the  DED1  of  MC159  mediates  direct
interaction with the IKK subunit IKKγ (also known as NEMO) and that this
interaction correlates with NF-κB signalling inhibition. Nevertheless, the exact
mechanism of how the described MC159-NEMO interaction abrogates NF-κB
signalling remained unknown at that time. Just recently, Biswas & Shisler
published their work uncovering the underlying mechanism [85]. IKKγ, aka
NEMO, needs to undergo polyubiquitination before NF-κB can be activated
downstream via IKK. The cellular E3 ligase which ubiquitinates NEMO is the so-
called “cellular inhibitor of apoptosis protein 1” (cIAP1). While binding to NEMO,
MC159 and cIAP1 were shown to occupy similar surface regions, suggesting a
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competitive behaviour of the two proteins towards the binding to NEMO. This
hypothesis could be proven correct by the demonstration that MC159 is indeed
able to outcompete cIAP1 from binding to NEMO [85].
Figure 6. M159-mediated inhibition of death receptor-induced apoptosis and NF-kB
signalling. By a novel mechanism, named “capping” [79], MC159 interferes with DISC-
assembly and procaspase 8 cleavage, what subsequently leads to apoptosis inhibition. By
direct binding to IKK component NEMO and outcompeting cIAP1, MC159 inhibits TNF-
mediated NF-κB signalling [80].
1.5.4.2.3.MC159 and IIRF3 inhibition
The activation of interferon response factor 3 (IRF3) is essential for interferon-β
gene expression. It is next to apoptosis and NF-κB activation the third component
of the “triad of intrinsic immune responses”, which is essential for the host cell
defence against pathogens [86]. Via interaction with TANK-binding kinase 1
(TBK1) and IKKγ, MC159 prevents TBK1 phosphorylation, which subsequently
prevents IRF3 phosphorylation and downstream activation of interferon-β gene
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expression. Interestingly, it is the DED2 of MC159, which promotes this function.
However, the precise mechanism underlying this observation remains to be
elucidated [86].
1.5.4.2.4.Inhibition of autophagy by MC159
In a study from Lee and colleagues from the year 2009 [71], MCV159 was along
with other viral, but also cellular FLIPs, identified as a negative regulator of
autophagy. By interacting with the Atg3 E2-like enzyme, MC159 and the other
FLIPs prevented Atg3 from binding and processing LC3 to LC3-II, which is an
essential requirement for autophagosome biogenesis. Moreover, the study
identified two critical regions in the viral FLIP’s DEDs- the alpha2-helix in DED1
and the alpha4-helix in DED2 (and homologue sites in cellular FLIPs) mediating
the interaction with Atg3. Interestingly, the peptides alone were able to bind to
Atg3 and FLIPs and could counteract the FLIP mediated suppression of autophagy
[71].
1.6. SH3 binding protein 4 (SH3BP4)
In 1999, SH3BP4 was described for the first time after its cDNA was isolated and
sequenced from human corneal fibroblasts [87]. The gene encoding the protein
is localized on chromosome 2q37.1-q37.2 from which a 5.1 kb messenger RNA is
translated. Initially, SH3BP4 mRNA was detected in pancreas, heart, kidney and
placenta. However, evidence on protein expression level was missing at that
time [87]. Today, 20 years later, SH3BP4 mRNA is known to be expressed almost
ubiquitously in the human body, and its expression on a protein level is proven
in numerous tissues, including higher expression levels in brain, muscle, lung,
liver & gallbladder, pancreas, gastrointestinal tract, male tissues and skin [88].
Figure 7. Schematic representation of human SH3BP4. ZU5: domain which is found in mouse
ZO-1 tight junction protein and C. elegans unc-5 protein; DD: death domain; PxxP motif: SH3
domain binding consensus sequence; N-P-F motif: EH domain binding site, adapted from [82]
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1.6.1. Characteristics of protein structure
SH3BP4 is a 963 amino acid polypeptide, which has a resemblance to members
of the “Eps15-Homology (EH) network family” [89]. Proteins belonging to this
network are mainly involved in endocytosis and vesicle-mediated transport [90].
The structural hallmarks of SH3BP4 support the protein in being an EH-network
family member. These hallmarks include three copies of the asparagine-proline-
phenylalanine (N-P-F) tripeptide (considered to be the core binding site of EH
domains), an SH3 domain, a LIDL-motif (a motif putatively involved in clathrin
binding) and a WXXF motif (supposedly mediating interaction with the AP2
adaptor complex) [91]. Further, SH3BP4 contains a C-terminally located death
domain (DD) and a ZU5 domain (named after the ZO-1 tight junction protein from
mouse and the uncoordinated protein 5 aka unc-5 from C. elegans, which both
contain this domain). Interestingly, a C-terminal death domain can mostly be
seen in eukaryotic proteins containing a ZU5 domain. The same is true for the
existence of an N-terminally located SH3 domain. ZU5 domains have been
reported to function in ankyrins as spectrin-binding domains, to be involved in
apoptosis induction and further in binding to melanoma-associated antigen D1
(MAGE-D1) [92].
1.6.2. Functions of SH3BP4
1.6.2.1. Transferrin receptor-trafficking
The first identified function for SH3BP4 supported the previously drawn,
structure-based conclusions for the possible involvement of SH3BP4 in
endocytosis and vesicle transport [93]. SH3BP4 or “Transferrin receptor
Trafficking Protein (TTP)-how the protein is called in this study, was identified to
be selectively involved in transferrin receptor (TfR) internalization regulation,
thereby supporting the hypothesis of a “cargo-specific mechanisms of receptor
internalization”, which the authors proposed. However, the molecular
mechanism could not entirely be clarified, leading to three possible scenarios
introduced by the study how SH3BP4 aka TTP acts on the regulation of TfR
internalization- 1) SH3BP4 functions due to simultaneous binding to TfR and
clathrin, with a possible synergetic effect of activating protein2 (AP-2), as TfR-
specific adaptor. 2) Function as “scaffold coordinator”, where SH3BP4 supports
the recruitment of TfR and dynamin (which can also be bound by SH3BP4) to
maturing clathrin-coated pits (CCPs) and thereby facilitates the localization of
these proteins to the pit/ fission machinery. 3) The so-called “vesicle loading
hypothesis”, suggests a model where SH3BP4 recruits dynamin via direct
interaction to the CCPs and inhibits its GTPase activity. At the same time, the
concentration of TfR in the CCPs increases what causes TfR to outcompete
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dynamin in binding to SH3BP4. This model would allow time and concentration
controlled fission of the CCPs. Importantly, the study also showed that SH3BP4
could be tyrosine-phosphorylated by the epidermal growth factor receptor
(EGFR) kinase, which subsequently regulated its interaction dynamin and
possibly with other interaction partners [93].
1.6.2.2. FGF receptor trafficking
The involvement of SH3BP4 in fibroblast growth factor receptor (FGFR) signalling
identified another cellular pathway were SH3BP4 acts on endocytic and vesicular
trafficking [94]. Upon FGFR2b stimulation by FGF-10, FGFR2b gets
phosphorylated what leads to the recruitment of PI3K via the SH2 domain of its
regulatory subunit p85. P85, in turn, could be shown to associate with SH3BP4,
mediated by the SH3 domain of SH3BP4. This interaction is required for sorting
of internalized FGFR2b to recycling endosomes and prevents the receptor from
being addressed for degradation, which leads subsequently to “increased cell
migration and epithelial branching” [94].
1.6.2.3. Negative regulation of mTORC1 signalling
The Rag GTPase complex is a critical component for amino acid-dependent
mammalian target of Rapamycin complex 1 (mTORC1) activity. It consists of four
members  of  Rag  GTPases-  RagA,  RagB,  RagC  and  RagD,  whereas  two
heterodimers build up the Rag GTPase complex . Depending on whether GTP or
GDP is bound to the RagA/ RagB heterodimer, mTORC1 can be activated, where
the GTP bound form mediates mTORC1 activation. The activation of mTORC1
leads subsequently to inhibition of macroautophagy [91]. In this context, SH3PB4
identified as a negative regulator of mTORC1 signalling. By binding and stabilizing
the inactive form of the Rag complex under amino acid starvation, SH3BP4
prevents the mTORC1-Rag GTPase interaction. As a result, mTORC1 cannot
localize to the lysosome and macroautophagy is induced [95].
1.6.2.4. Additional functions of SH3BP4
A  recent  study  from  O'Loughlin  and  colleagues  [96]  reported  SH3BP4  as  a
component of the so-called “LIFT complex”, which is a protein complex
consisting of the four proteins: myosin 6 (MYO6), GAIP C-terminus-interacting
protein (GIPC1), leukaemia-associated RhoGEF (LARG) and SH3BP4. The term
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“LIFT” stands for LARG-Induced F-actin for Tethering, and the complex was
shown to be essential for modulation of actin at early endosomes [96].
Another novel function of SH3BP4 was proposed by Antas and colleagues [97].
The study stated that by modulating the subcellular localization of β-catenin,
SH3BP4 acts through negative feedback inhibition on Wnt-signaling. The ZU5
domain of SH3BP4 could be identified as the region, which is promoting this
function [97].
1.7. Cellular autophagy
Autophagy, translated from Greek as “self-eating”, defines the cellular process
of the highly regulated and coordinated degradation and recycling of cellular and
foreign components. More specifically, the degraded components include
soluble and aggregated proteins, cell organelles, macromolecular complexes and
pathogens [98]. In mammalian cells, three types of autophagy are described,
macroautophagy, microautophagy and chaperon-mediated autophagy (CMA).
While all three autophagy types share the final step of cargo delivery to the
lysosome, followed by cargo-degradation or recycling, the respective upstream
processes are distinct [99]. The process of macroautophagy has been extensively
studied during the last decades and is in the literature commonly referred to as
“autophagy”.  For this reason and the impact of macroautophagy in the later
presented and discussed study, it will be the type of autophagy introduced in the
following in more detail.
1.7.1. General overview macroautophagy
Macroautophagy divides into non-selective or “bulk autophagy” and selective
autophagy. Non-selective autophagy occurs continuously at basal levels and has
a major role in sustaining cellular homeostasis. It is a catabolic process
converting cytoplasmic material into metabolites, which can then be used in
anabolic and energy-producing processes of the cell [100]. Under conditions of
nutrient or energy starvation, the process can further be activated to provide the
cell with the necessary metabolites. Unlike bulk autophagy, selective autophagy
targets specific objects inside the cell. The terminology used for the different
types of selective autophagy depends on the targeted objects. Examples are
“mitophagy” (selective degradation of mitochondria), “aggrephagy” (selective
degradation of aggregated proteins), “xenophagy” (selective degradation of
intracellular pathogens), “peroxypahgy” (selective degradation of peroxisomes)
and others [101, 102]. Importantly, each type of selective autophagy is mediated
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by a defined set of so-called “autophagy receptors”- proteins which identify their
specific cargo and deliver it via an interaction with the autophagy-related protein
8  (ATG8)  aka  light-chain  3  (LC3)  for  lysosomal  degradation  [100].  P62/
Sequestome 1 (SQSTM1) is the autophagy receptor which has been studied
intensively, due to its involvement in almost every known type of selective
autophagy [103]. Another important autophagy receptor which is involved in
xenophagy, aggrepahgy and mitophagy is optineurin (OPT) [104].
Figure 8. Graphical overview of autophagy stages. © Current Biology, Elsivier, reproduced
with permission from Kast et al. [105].
1.7.2. Components and mechanisms
The autophagy process can be divided into six steps promoting the lysosomal
elimination of intracellular material of own or foreign origin. When looking at the
induction of autophagy, the first step, called “Initiation” (Fig. 8 A) is preceded by
signals impinging the cell under starvation conditions. Signals arising from amino
acid, energy or growth factor depletion are recognized and forwarded by
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different receptors and signalling cascades. However, all those signals lead to
mTORC1- the key regulator of mammalian autophagy. When mTORC1 is inactive,
autophagy initiation occurs by formation of the ULK-complex and the activation
of death-associated protein 1 (DAP1). The regulation of mTORC1 by amino acids
is mediated via several amino acid transporters (AAT) and small Rag GTPases.
The Rag GTPases form complexes of two heterodimers each containing two of
the four different Rag GTPases. This Rag GTPase complex recruits mTORC1 to the
lysosomal membrane, which is essential for mTORC1 activity. The regulation of
mTORC1 activity by growth factors is, on the other hand, transmitted via the
PI3K- Protein Akt/ Tuberous sclerosis (TSC)-Ras homolog enriched in brain (Rheb)
pathway. Last but not least, low energy levels lead to 5' AMP-activated protein
kinase (AMPK) activation, what in turn inhibits mTORC1 function by activation of
TSC2 and phosphorylation of the Regulatory-associated protein of mTOR
(Raptor) [105]. Upon initiation, the ULK1/Atg1 complex activates PI3K class III
complex, which is recruited to the endoplasmatic reticulum (ER). There the
complex generates phosphatidylinositol-(3)-phosphate (PIP3), which leads to
sites at the ER enriched in PIP3. These PIP3-rich ER membrane regions are
precursors for the forming autophagosomes, what is at this stage, also known as
“omegasome” [106, 107]. During the next step, the “formation” (Fig. 8 B), several
key proteins are recruited to this forming omegasome and aid mechanically its
further enlargement. The growing omegasome extends into the isolation
membrane, also known as “phagophore”. The phosphatidylethanolamine (PE)
conjugated form of the Atg8 family member LC3- called LC3-II, is inserted in the
phagophore membrane. In selective autophagy LC3-II functions as an anchor for
autophagy adaptor proteins such as p62 or optineurin, which carry the
ubiquitinated cargo to be degraded along with them. As mentioned above, this
cargo includes mitochondria, protein aggregates, peroxisomes and intracellular
pathogens [103). During the following “expansion” (Fig. 8 C) the phagophore
further extends, and more ubiquitinated cargo is delivered. When the
phagophore closes, the mature autophagosome will move on to the
“detachment and transport” phase, where it releases from the membrane of the
ER and is transported first via an “actin comet tail mechanism” [106]. The “long-
range transport” (Fig. 8 D) as the next step is supported by dynein-dynactin
carrying the autophagosome by moving along microtubules [108]. The last
“fusion and degradation” (Fig. 8 F) phase consists of the fusion of the
autophagosome with a late endosome, what forms the amphisome and its
subsequent fusion with a lysosome, forming the autolysosome. Due to the acidic
pH of the lysosome, the pH of the autolysosome is also acidic, which causes the
activation of hydrolytic enzymes which subsequently degrade the content of the
autolysosome [106].
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1.7.3. Exploration of autophagy by viruses
Autophagy is a powerful host cell defence mechanism against viral infections,
whereas several different aspects of autophagy promote this function. 1)
Autophagosomes trap and deliver viruses which have entered the cell to
lysosomal degradation via a form of selective autophagy named “xenophagy”
(with the important note that xenophagy traps different types of pathogens, not
only viruses) [109]. 2) The autophagy machinery contributes to the innate
immune response via pattern recognition receptors (PRR) signalling and
subsequent interferon production [110]. 3) Further, it also promotes adaptive
immunity by delivering virus-derived antigens for the presentation to T-
lymphocytes [111]. During virus evolution, viruses continuously adapt to their
host cell by hijacking and modulating cellular signalling pathways to ensure
replication and thereby survival. Therefore, it is no surprise that viruses also
developed different strategies to oppose or utilize autophagy for their own
needs [112]. Depending on the virus lifecycle and characteristics of infection,
autophagy is either blocked or employed by different viruses. Persistent viruses
like human herpes virus-1 (HSV1), Kaposi’s sarcoma-associated herpesvirus
(KSHV), MCV and other DNA-viruses have established numerous methods to
avoid or inhibit different steps of autophagy. In contrast to that, RNA viruses like
flavi- or picornaviruses depend in certain stages of their lifecycle on the
autophagy machinery and exploit it for their needs [112-114].
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2. Aims of the study
The aim of this doctoral thesis was the identification and characterization of
novel, high-affinity SH3 domain-mediated interactions in the context of i) the
human SH3 domain interactome and ii/iii) viral infections, namely, IAV and MCV.
The specific goals were:
i. The identification of selective and strong SH3 domain-mediated
interactions from the human SH3 interactome and thereby generate a
valuable resource of leads for further investigations
ii. To understand the role and consequences of the SH3 domain-mediated
IAV NS1 protein-Crk(L) interaction in the context of PI3K activation and its
downstream effector Akt.
iii. The validation of MCV MC159 protein as potential SH3 domain ligand and
to identify its preferred SH3 domain-containing interaction partner.
Furthermore, to determine the impact of MC159-SH3 binding on host
cellular signalling.
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3. Material and Methods (study I-III)
3.1. Expression vectors
Expression vectors (I)
To generate  the expression vectors  for  the potential  SH3 ligand proteins,  449
open reading frames (ORFs) encoding for these ligands were acquired from the
ORFeome v3.1 library (Lamesch, P., Milstein, S. 2007) and inserted via Gateway
cloning strategy into the destination vector pEBB/PP-DEST. pEBB/PP-DEST is a
modified pEBB/PP vector (gift from Bruce Mayer, University of Connecticut
Tanaka et al. 1995) which is driven by an EF-1alpha promotor and contains a 123
amino acid biotin acceptor domain (PP domain)), where a fragment of the
modified pDEST vector (gift from Jussi Taipale, University of Helsinki, Finland) has
been inserted. The fragment contained the recombination sites attR1 and attR2,
the chloramphenicol resistance- and ccdB genes. For individual recombination
reactions, the Gateway LR Clonase II Enzyme Mix (Invitrogen, Carlsbad,
California, USA) was used according to the manufacturer’s protocol. As a result
of the Gateway cloning, each potential SH3 ligand ORF was cloned in frame with
an N-terminal PP domain.
Expression vectors (II)
The expression vectors for the N-terminal Myc-tagged NS1 proteins
(A/Mallard/Netherlands/12/2000/H7N3), A/Udorn/72 and A/WSN/33), were
generated by inserting the NS1 cDNAs into pEBB/myc. The cDNA for A/Mallard
NS1 generated from total RNA extracted from cells infected with
A/Mallard/Netherlands/12/2000/H7N3 IAV, the cDNAs for A/Udorn/72 and
A/WSN/33 NS1 proteins were a gift from Ilkka Julkunen (University of Turku,
Finland). The C-terminally PP domain tagged Crk proteins (CrkI, CrkII and CrkL)
created by inserting Crk protein cDNAs into pEBB/PP. The cDNA for mouse p85β
(Open Biosystems) was inserted into pEBB/HA or pEBB/PP for mammalian
expression  of  N-terminal  HA-or  PP-tagged  p85β.  All  codon  changes  in  NS1  or
p85β were carried out by standard overlap PCR mutagenesis. For the generation
of the bacterially expressed Glutathione S-transferase (GST)- and maltose-
binding protein (MBP) tagged NS1 proteins, NS1 cDNA was cloned into the pGEX-
4T-1 vector (GE Healthcare, Chicago, Illinois, United States) and pMAL-c2x (New
England Biolabs, Ipswich, Massachusetts, USA).
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Expression vectors (III)
The sequence encoding the MC159L gene of molluscum contagiosum virus
(EMBL AAC55287.1) was purchased as synthetic gene fragment from GeneScript
(NJ, USA) and cloned into two variants of the pEBB mammalian expression
vector, containing either an N-terminal hemagglutinin (HA) or PP tag. All amino
acid substitutions of the MC159 variants- MC159AxxA(N), MC159AxxA(C) and
MC159AxxA(N+C) were generated by overlap PCR mutagenesis. Human SH3BP4
cDNA (NCBI GeneID 23677) was inserted into the mammalian expression vector
PCMV/myc-DEST- a modified version of the pCMV-DEST vector, containing a Myc
epitope (study II) via Gateway cloning. The NF-κB-driven firefly luciferase-
expressing vector pBIIX was previously described [115]. To create the lentiviral
expression vector pWPI-puro, the EGFP gene in pWPI (from Didier Trono
[plasmid 12254; Addgene, Cambridge, Massachusetts, USA]) was replaced with
the puromycin resistance gene. For lentiviral transduction and subsequent cell
imaging analysis, a fusion construct of each- MC159 and MC159AxxA(N) with a C-
terminally added mCherry was subcloned into the pWPI-puro expression vector.
For the generation of SH3BP4 Knockout cells used CAG-Cas9-T2A-EGFP-ires-puro
expression vector was a gift from Timo Otonkoski (plasmid 78311; Addgene),
SH3BP4 genomic RNA (gRNA; BRDN0001487091) was a kind donation from John
Doench and David Root (plasmid 78089; Addgene).
3.2. Cell Culture (I, II, III)
Human Embryonic Kidney 293T (HEK293T) cell line from ATCC (I, II, III), human
hepatocellular carcinoma (Huh-7, obtained from Mark Harris, University of
Leeds, UK) cell  line (II),  human cervix epitheloid carcinoma (HeLa) cell  line (III)
and Human Caucasian breast adenocarcinoma (MCF7, stably expressing LC3-
EGFP “MCF7/LC3-EGFP”, obtained from Marja Jäätelä, DCRC Copenhagen,
Denmark) cell line (III) were grown in Dulbeccos Modified Eagle Medium (DMEM)
(Sigma Aldrich, St. Louis, MO, USA) supplemented with 4500 mg/L of glucose,
10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA), 0.05 mg/mL penicillin,
0.05 mg/mL streptomycin (Sigma Aldrich), and 1 mM L-Alanyl-L-glutamine
(Sigma Aldrich) at 37C in 5% CO2. For the induction of autophagy in MCF7/LC3-
EGFP cells, Hank’s Balanced Salt Solution with CaCl2 and MgCl2 (HBSS, Gibco,
Carlsbad, CA, USA) was applied.
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3.3. Generation of knockout cell lines and lentivirus-mediated gene
transduction (III)
MCF7/LC3-EGFP were co-transfected with 1.6 μg of SH3BP4 gRNA plasmid
(Addgene, Cambridge, Massachusetts, USA) and 0.6 μg of Cas9 expression vector
with TransIT-2020 transfection reagent (Mirus Bio, Madison, Wisconsin, USA)
following the manufacturer’s instructions. 48 hours post-transfection, cells were
subjected to puromycin selection for two days at 4 μg/ml puromycin.
Afterwards, cells were recovered in regular cell culture medium and
subsequently diluted into 96-well plates to perform a single-cell selection.
HEK293T cells were co-transfected with pWPI-MC159-mCherry expression
vectors, pDelta8.9 and vesicular stomatitis virus G protein (VSV-G) expressing
plasmids using Polyethylimine (PEI) transfection method (3.4.). 48 hours post-
transfection, the supernatant was collected and filtered. The filtered lentivirus-
containing supernatant was used to infect wild-type or SH3BP4 knockout
MCF7/LC3-EGFP cells. Successfully infected cells, stably expressing MC159-
mCherry proteins, were selected with puromycin.
3.4. Transfections (I, II, III)
Calcium phosphate precipitation transfection method was applied to HEK293T
cells (I, II, III) following the protocol for transfection of a 10 cm cell culture dish
(protocol was adjusted according to the number of transfected cells): 20 µg of
plasmid DNA were diluted into 250 µl sterile water and then mixed with 250 µl
2,5M CaCl2. The mixture was added dropwise into 500µl 2x HeBS (274 mM NaCl,
10 mM KCl, 1.4 mM NaHPO4, 15 mM glucose, 42 mM Hepes, pH 7.05) under
vortexing. The transfection mix was incubated 15- 30 minutes at room
temperature (RT) and then added dropwise onto the cell culture medium. The
medium and added transfection mix were mixed carefully, and cell culture
medium was refreshed 24h post-transfection. PEI (Polyscience Inc.,
Pennsylvania, USA) transfection was used to transfect HEK293T cells (III) and
HeLa cells (III) following the protocol: 12 µg of plasmid DNA were diluted into
300 µl Opti-MEM (Thermo Fisher Scientific, Massachusetts, USA) and mixed with
24 µl PEI. Following an incubation of 15- 30 minutes at RT, the transfection mix
was added dropwise in the cell culture dish, which was then chucked carefully to
blend the mix into the cell culture medium evenly. Lipofectamine2000
(Invitrogen, Carlsbad, CA, USA) was used according to the manufacturer’s
instructions for transfection of Huh-7 cells (II). For luciferase assays (III), HEK293T
cells were transfected using Fugene6 (Promega, Wisconsin, USA).
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3.5. Antibodies and reagents (I, II, III)
Primary antibodies used in (II): mouse anti-Myc (9E10, Santa Cruz Biotechnology,
Dallas, Texas, USA), mouse anti-CrkL (clone 5–6, Merck Millipore, Burlington
Massachusetts, USA), mouse anti-HA (F-7, Santa Cruz Biotechnology), rabbit anti-
phospho Akt(Ser473) (D9E, Cell Signaling Technology, Danvers, Massachusetts,
USA), mouse anti-Akt (40D4, Cell Signaling Technology), mouse anti-p85β (T15,
AbD Serotec, Kidlington, UK), mouse anti-α-tubulin (DM1A, Sigma-Aldrich, St.
Louis, Missouri, USA) and guinea-pig anti-NS1 [116]
Primary antibodies used in (III): mouse anti-Myc (clone 9E10; Santa Cruz
Biotechnology, Texas, USA), mouse anti-SH3BP4 (A6; Santa Cruz Biotechnology),
mouse anti-caspase-3 (BD Bioscience, California, USA), mouse anti-caspase-8
(1C12; Cell Signaling Technology) rabbit anti-LC3B (D11) XP (Cell Signaling
Technology), mouse monoclonal (6G6) to red fluorescent protein (RFP)
(ChromoTek, Munich, Germany), rabbit anti-GFP (sc-8334; Santa Cruz
Biotechnology), and rabbit anti-p62 (Enzo, New York, USA).
Secondary antibodies used: IRDye 680CW goat anti-mouse IgG (II, III) IRDye
800CW  goat  anti-mouse  IgG  (II),  IRDye  680CW  goat  anti-rabbit  IgG  (II)  IRDye
800CW goat anti-rabbit IgG (II, III), Streptavidin IRDye680CW (II), Streptavidin
IRDye800CW (I, II, III) were from Li-Cor Biotechnology (Lincoln, Nebraska, USA).
IRDye800CW rabbit anti-guinea pig (II) was purchased from Rockland
Immunochemicals (Pottstown, Pennsylvania, USA).
Reagents: Imatinib (II, c-Abl inhibitor) was purchased from Sigma-Aldrich.
Cycloheximide was a kind gift from Tomas Strandin (University of Helsinki,
Finland).
3.6. Recombinant protein expression (I, II)
GST-fusions of SH3 domains (I) and NS1 proteins (II) were expressed in E.coli BL21
and affinity purified using glutathione-sepharose 4B (GE Healthcare). MBP-NS1
proteins (II) were expressed similarly and affinity purified with amylose resin
(New England Biolabs, Ipswich, Massachusetts, USA).
3.7. Phage Display library-based screening (I, III)
3.7.1. Protein expression and cell lysis (I)
10 cm cell culture dishes of HEK293T cells were transfected with pEBB/PP ORF
expression vector or pEBB/PP control plasmid by standard calcium phosphate
precipitation method (see “Transfections”). 36 h post-transfection, cells were
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collected in ice-cold PBG buffer (1× phosphate-buffered saline (PBS)
supplemented with 10% glycerol and 0.5% Tween-20, supplemented with
protease inhibitors “complete” from Roche, Basel, Switzerland). Cell lysis was
continued by sonication at 0.2- 0.3 kJ on ice using a Bandelin Sonoplus
homogenizer (Berlin, Germany). The cell lysates were cleared by centrifugation,
20 minutes at 13200 rpm and 4°C.
3.7.2. Protein expression and cell lysis (III)
Subconfluent HEK293T cells in 10 cm cell culture dishes were transfected with
pEBB/PP-MC159 constructs either by standard calcium phosphate precipitation
method or using PEI transfection protocol (see 3.3. [III]) 48 h post-transfection,
cells were collected in ice-cold TEN (50 mM Tris [pH 7.4], 1 mM EDTA, 150 mM
NaCl) buffer. Afterwards, cells were pelleted at 4°C, and 1500 rpm and the cell
pellet was frozen at -80°C. Cells were thawed on ice and lysed in a volume of 1
ml lysis buffer (phosphate-buffered saline [PBS], 1.2% [V/V] NP-40, protease
inhibitor [Thermo Fisher Scientific, Massachusetts, USA]). Following, the cell
lysates were sonicated twice, 10 seconds at 50% amplitude with a Bandelin
Sonoplus homogenizer and cell debris was removed by spinning the cell lysates
at 4°C and 132000 rpm for 20 minutes.
3.7.3. Protein pull-down and panning
PP-tagged ligand proteins were precipitated with streptavidin-coated magnetic
beads (Dynabeads M-280-Streptavidin, Invitrogen, Carlsbad, California, USA) by
incubation of the cell lysates with magnetic beads for 90 minutes at 4°C under
rotation. Following, the beads were washed one time with 1 ml cold lysis buffer
and another two times with 1 ml cold PBST (0.05% Tween-20 in 1× PBS). Each
wash was done for 1 minute under rotation.
For phage-library panning, the magnetic beads, containing the ligand-protein,
were incubated with a mixture of human SH3 library-displaying phages (about 1
× 1011 colony-forming units [CFU]) and 5% milk in PBST. The ratio of phage
solution to milk in PBST was 2:1, and the bead-phage mix was incubated at RT
and under rotation for 120 minutes (I) or 90 minutes (III). After incubation, beads
were washed with 1 ml PBST four times for 5 minutes under rotation, whereas
the reaction tubes were changed after the first and third wash. Meanwhile, TG1
bacteria were grown to log-phase (OD 0.5- 0.6), and 800 µl of TG1 bacteria were
mixed with the beads after the last wash, containing now the ligand-protein and
the bound phages. The mix was incubated, shaking at 37°C for 1 hour. Finally,
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bacteria were plated in different dilutions lysogeny broth (LB) plates containing
ampicillin. To identify the ligand-protein interacting SH3 domains, the formed
bacterial colonies and their SH3 domain-encoding phagemids (pG8J8/SH3
clones) were subjected to Sanger sequencing.
3.8. Cellular protein interactions (II, III)
3.8.1. Immunoprecipitation and protein pull-down (II)
Transfected HEK293T cells were collected in ice cold TEN buffer as described in
(3.6.2.)  and lysed in 1% NP40 buffer (150 mM NaCl,  50 mM Tris-HCl,  1% [V/V]
NP40, pH 7.9, including protease and phosphatase inhibitors). For
immunoprecipitation, cell lysates were incubated with protein G magnetic beads
(Dynabeads, Invitrogen, Carlsbad, California, USA), which were beforehand
conjugated with anti-CrkL or anti-HA antibodies. For pull-down experiments, cell
lysates were incubated with streptavidin-coated magnetic Dynabeads
(Invitrogen, Carlsbad, California, USA).
3.8.2. Protein pull-down (III)
HEK293T cells were transfected as described in (3.4.). Importantly, for
interaction studies of MC159 and SH3BP4, the ratio of transfected pEBB/PP-
MC159 to PCMV/myc-DEST-SH3BP4 plasmid DNA was 3:1. Cells were collected
as described in (3.6.2.) and lysed in 1 ml of HEPES-based lysis buffer (40 mM
HEPES, 120 mM NaCl, 10 mM glycerophosphate, 1% [V/V] Triton X-100, including
protease and phosphatase inhibitor minitablets [Thermo Fisher Scientific,
Massachusetts, USA]). Lysates were incubated on ice for 20 min and cleared by
centrifugation. Following, the lysates were incubated for 90 min at 4°C, under
rotation, with streptavidin-coated magnetic Dynabeads (Invitrogen, Carlsbad,
California, USA).
3.9. Gel electrophoresis and Western blotting and detection (I, II, III)
All protein samples subjected to Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) were mixed before with 4x Laemmli buffer (200 mM
Tris-HCl pH 6.8, 8% w/v SDS. 0.4% w/V bromophenol blue. 40% V/V glycerol, 5%
V/V β-mercaptoethanol), boiled 5 min at 95 C and immediately transferred on
ice. After preparation, protein samples were separated by SDS-PAGE and
transferred on nitrocellulose by semidry Western blotting technique (Biorad,
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Hercules, California, USA). Visualization of specific protein signals was done using
the Odyssey infrared imaging system from LI-COR Biosciences.
3.10. Peptide Array (I)
The peptides were synthesized by the former “Peptide and Protein Laboratory”
(Haartman Institute, University of Helsinki, Finland) and spotted on cellulose
using the Multipep system (Intavis Bioanalytical Instruments, Cologne,
Germany). The SPOT synthesis was carried out according to the manufacturer’s
protocol [117]. Parallel arrays were prepared on glass slides with the SlideSpotter
equipment (Intavis Bioanalytical Instruments). The spotted peptide arrays were
incubated in blocking solution (PBST, 5% w/V nonfat dry milk) for 2 hours and
washed three times with PBST. SH3 domains which were identified by the
preceded phage screen as strong interaction partners to at least one of the ligand
proteins (Lyn, Src, Fyn, Tec, Yes, Crk, CrkL, Amphiphysin (AMPH), CMS (1/3),
BAIAP2L1, ArgBP2, Eps8L3, Intersectin 1 (Itsn1) (3/5)) were expressed and
affinity-purified from bacterial cultures as GST-fusion proteins. The peptide
arrays were incubated with individual SH3 domains, which were beforehand
diluted to a final concentration of 1 µM in blocking solution, for 1 hour at room
temperature. Following, the slides were washed three times with PBST and once
with PBS. To detect SH3 domain binding, peptide array slides were incubated
with anti-GST antibody, which was later conjugated with dye IRDye 800CW (LI-
COR Biosciences). The signals were imaged and quantified using the Odyssey
infrared imaging system from LI-COR Biosciences. The interaction strength of the
individual SH3 domains with each peptide was estimated from the detected
signal of the corresponding spot in the arrays. The binding was considered
specific, if the signal exceeded or was equal to 50% of the highest intensity value
from the evaluated array.
3.11. Semi-quantitative pull-down assay (I)
The SH3-GST-pp fusion proteins were expressed and purified as described before
(3.5.). The purified fusion-proteins were dialyzed against NP40 lysis buffer (pH
7.4) and adjusted to a final concentration of 0.5 µM.  Free biotin was added to
the solution to a final concentration of 500 µM. The SH3 domain ligand proteins
were expressed and captured by streptavidin-coated magnetic Dynabeads
(Invitrogen, Carlsbad, California, USA) from HEK293T cells as described in 3.6.2.
and 3.6.3.. To saturate all remaining free biotin-binding sites on the streptavidin-
coated magnetic beads after ligand-immobilization, free biotin was added to a
final concentration of 500 µM. Following, the beads containing the ligands were
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washed three times with NP40 lysis buffer and incubated with the recombinant
expressed and purified SH3-GST-pp fusion proteins for 1 hour at 4°C under
rotation. The magnetic beads, containing the ligand and putatively bound SH3-
GST-pp fusion proteins, were washed three times with lysis buffer. The protein
complexes were separated and analysed by SDS-PAGE and Western blotting as
described in (3.8). The signals of the bound SH3-GST-pp fusion proteins were
quantified with the Image Studio™Lite Software (LI-COR Biosciences) and plotted
against the ration of these signals vs the total concentration of SH3-GST-pp
fusion protein incubated with the ligand. To calculate KD-values, a linear
regression model was applied to the plotted data, and the regression line slope
provided the negative KD-value.
3.12. NF-κB luciferase reporter assay (III)
HEK293T cells were transfected with 50 ng of pEBB-HA-RenLuc, 50 ng of NF-κB-
driven pBIIX-fLuc DNA and pEBBHA-MC159 DNA using Fugene 6 (Promega, WI,
USA) in accordance with the manufacturer’s protocol. At 24 h post-transfection,
the cell culture medium was changed to medium containing 10 ng/ml TNF-α.
After 8 hours of treatment, cells were washed with ice-cold PBS and lysed on the
plate in 100 µl passive lysis buffer (Promega, WI, USA). To determine luciferase
activities, the dual-luciferase reporter assay system from Promega was used
following the manufacturer’s protocol. The measured Renilla luciferase was used
as an internal control.
3.13. TNF-induced apoptosis (III)
HeLa cells were transfected either with pEBBHA-MC159 DNA or control plasmid.
The treatment of cells with 10 ng/ml TNF-α and 10 μg/ml cycloheximide was
done 24 hours post-transfection for 8 hours. Following treatment, cells were
washed with ice-cold PBS and lysed on plate in 200 µl NP40 lysis buffer (pH 7.4).
All samples were analysed as described in 3.9.
3.14. Autophagy analyses (III)
MCF7 cells expressing LC3-EGFP (macroautophagy marker) alone or stably co-
expressing wild-type MC159- or MC159AXXA(N)-mCherry fusion proteins were
seeded on 13-mm-diameter coverslips, 1.5 mm, 24 hours after seeding and two
washes with PBS, cells were either incubated with HBSS (starvation) or complete
cell culture medium (untreated) for 6 hours. Following, cells were fixed with 4%
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paraformaldehyde (PFA) for 15 min and washed three times with PBS.
Subsequently, mounting of the cells on microscope slides was done using
Hoechst stain (nuclear marker) containing mounting medium. Imaging of the
slides was done using an Axio Imager Z2 upright epifluorescence microscope
(Carl Zeiss Microscopy, GmbH, Germany) with a 20× (numeric aperture [NA],0.8)
air immersion objective with a Hamamatsu Orca Flash 4.0 LT, 4-megapixel
monochrome sCMOS camera. Images of three fluorescence channels were
taken- nuclear (DAPI), EGFP, and mCherry, whereas three image stacks were
taken for each position. The Huygens batch processing application (scientific
volume imaging; Huygens Software) was used for deconvolution of the images.
Three independent experiments, including all 12 experimental conditions (wild
type, mutant, or control/starvation or no treatment/parental MCF-7/LC3-EGFP
cells or their SH3BP4 knockout derivatives) were performed. Quantitative
autophagosome analysis was performed with Imaris image analysis software 9.2
(Bitplane AG, Zurich, Switzerland). Statistical analysis of the data was done by
performing a Mann-Whitney U test using IBM SPSS statistics software.
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4. Results
4.1.1. Identification of human SH3 interactome ligands using phage-display
library screen approach (I)
With the goal to examine selective and affine SH3 domain-mediated interactions
in the human interactome, the Human ORFeome v3.1. cDNA library [118], which
contains the genetic information of human 10214 genes, was first screened
bioinformatically for potential SH3 domain ligands. The screening was based on
the identification of SH3 target motif sites in the potential ligands encoded by
the ORFeome library. The first of two applied SH3 target motif prediction
strategies was based on the identification of conventional SH3 binding motifs
such as PxxP as well as unconventional motifs like PxxDY, Px(P/A)xxR, φxRPxR,
and PxxxRxxKP (“x” stands for any amino acid and φ is a hydrophobic residue).
In a second approach, potential ligands were identified based on the existence
of regions with a high frequency of prolines or basic amino acid residues. We also
included several gene expression products from the library in the second
approach, which did not contain an apparent SH3 binding motif, but were known
to be involved in cellular signalling and contained at least one modular protein
domain such as SH3, SH2 or PDZ. The second screening approach was intended
to uncover novel types of SH3 interaction.
When combining the results of the described screening approaches, we
identified a total number of 449 sequences from the ORFeome cDNA library,
which potentially encoded an SH3 binding ligand (Supplementary Table S1 in I).
The group of proteins which contained at least one class I or II SH3 binding motif,
represented with 302 proteins, the largest group among the total 449 identified
potential ligands.
To express the potential SH3 binding ligands transiently in mammalian cells, we
subcloned the 449 ORFs into the pEBB/PP-Dest mammalian expression vector by
Gateway cloning. The pEBB/PP-Dest vector was driven by elongation factor 1 (EF-
1α) promoter and provided a biotin-acceptor- “PP” domain as fusion to the
expressed proteins of interest. The so expressed polypeptides were captured
with streptavidin-coated magnetic beads from HEK293T cell lysates and
subjected to a single round of SH3 phage-display library affinity screen (Fig. 1 in
I). Of the initial 449 identified genes, 324 could be successfully subcloned and
expressed from cells, resulting in proteins matching the predicted size (Table 1
& supplementary Table S1 in I). To estimate a sufficient expression/
concentration of the individual PP-tagged proteins in cell lysates, we compared
their corresponding Western blotting signals to the signal obtained from a cell
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lysate containing PP-PAK2 control protein, which was present in a concentration
known to be sufficient for successful phage-display screening.
A single round of phage-display affinity selection was applied to the 324
successfully expressed potential SH3 ligand proteins, which revealed 19 proteins
(5.6%) as strong and selective SH3 binders. “Strong” binding was defined as > 20
fold-enrichment of infectious phages associated with the potential ligand
compared to control beads (containing PP-domain only). “Selective” binding was
attributed when the selected SH3 domains were dominated by a single or few
individual SH3 domains. Another group of 25 proteins (7.7%) showed a
substantial enrichment between three to 20 fold of phages over control, but with
a lower SH3 domain selectivity. The majority of the 324 successfully expressed
proteins (86%) exhibited no significant phage-enrichment over control (less than
threefold) and/ or a lack of specificity (Table 1 in I).
Reviewing the existing literature on SH3-mediated interactions, we found that
some of the 19 proteins and their preferred SH3 domains, which we classified
based on the phage-display screening as “strong” and “selective” SH3
interactions (Table 2 in I), were previously described. One example was the
reportedly robust and highly selective interaction of GRB2-related adaptor
protein downstream of Shc (GADS aka Mona) and Src-homology 2 domain-
containing leukocyte phosphoprotein of 76 kDa (SLP-76 aka LCP2)[119]. Another
example was the interaction of Hematopoietic cell-specific Lyn substrate 1
(HCLS1) with Lyn SH3 domain [120]. Apart from these examples, all remaining
interactions we identified as strong and highly specific, were novel.
The results from the phage-display screening further supported the concept that
a significant fold-enrichment of phages for a certain ligand was associated with
high selectivity (Table 2 in II). For example, only a single SH3 domain was selected
by Calcium/calmodulin-dependent protein kinase type IV (CAMK4), Insulin
receptor tyrosine kinase substrate (IRTKS) and HCLS1, namely Btk, Eps8L3, and
Lyn, respectively. The majority (17 out of 19) of the identified strong and
selective SH3 domain ligands comprised in > 50% of the selected phage clones a
single SH3 domain. In two cases, Embryonal Fyn-associated substrate (EFS) and
Arg/Abl-interacting protein (ArgBP2), 50% or more of the bound phages
represented only two individual SH3 domains. For seven of the 19 proteins, we
performed sub-screenings in which we used independently produced infectious
SH3 phage libraries and ligand preparations. The obtained results
(Supplementary Table 2 in I) were similar to those from the initial phage
screenings and thereby confirmed the excellent reproducibility of this approach.
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4.1.2. Analysis and binding profiles of the SH3 ligand protein peptides
Since the 19 identified highly selective SH3 ligand-proteins contained up to 12
potential SH3 binding motifs, it was of great interest to understand the individual
binding properties of these motifs and their contribution to SH3 domain
interactions. For this purpose, a total number of 65 peptides was synthesized.
These peptides ranged between 15 and 17 amino acids in length, and their
sequences resembled the motifs on which we initially based the screening of the
ORFeome library for SH3 ligands (Table 3 in I).
To perform the peptide array, all 65 peptides were spotted on glass slides and
incubated with 16 individual SH3 domains, which were expressed and purified
from bacteria as GST-fusion proteins. The 16 SH3 domains included those, which
were preferentially bound by at least one of the 19 ligands from the phage
library. Due to insufficient recombinant expression or unspecific binding to the
glass slides, the SH3 domains of Btk, GADS and Eps8L3 could not be used as
probes in the peptide array. In the case of Eps8L3, we were able to produce the
homologous SH3 domain of Eps8L1 as a replacement. The 65 peptides were
spotted in two different schemes on the glass slides to prevent any position-
related bias, and each probing of the glass slides with the individual 16 SH3
domains was carried out in three independent experiments (Figure 2 in I).
To evaluate the peptide-binding properties from the peptide arrays, we
determined the relative binding signals of the peptides in the context of each
individual SH3 domain probe. For this purpose, the background fluorescence
signals were subtracted from the peptide spot signals, and the so obtained raw
signals were normalized to the average signal from all peptides.
The so determined individual binding capacities of the 65 peptides for the
probed SH3 domains were for simplification categorized into “negative”, “weak”,
“intermediate” and “strong” interactions. An interaction was defined as
“negative” when the individual peptide spot signal was less than 0.5 fold of the
average signal of all peptides in the array. “Weak” was attributed for signals
0.50–0.99 times the average peptide spot signal, “intermediate” for 1.0–1.99
times the average signal and all signals with values > 2 were defined as “strong”
interactions (Table 3 in I). We found, depending on the probed SH3 domain, 4.6–
23.1% (3–15 out of 65) of the peptides acting as “strong” binders. “Intermediate”
binders were represented by 6.2–43.1% (4–28 out of 65), “weak“ by 4.6–36.9%
(3–24 out of 65) and “negative” binders by 26.2–69.2% (17-45 out of 65).  The
differences between the peptide array results for the individual SH3 domains can
be explained on the one hand by their distinctive selectivity, but on the other
hand also by the experimental quality, which depended strongly on the signal to
noise ratio of each SH3 domain probe.
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According to the acquired results, the binding abilities and preferences of the 65
peptides towards the tested SH3 domains varied greatly. While ten peptides
behaved rather indiscriminately and showed “strong” or “intermediate” binding
to at least 13 of the 16 probed SH3 domains, many others were highly selective
in their binding. 37% of all arrayed peptides bound to three or fewer individual
SH3 domains. However, six peptides bound “strongly” to only one or two SH3
domains, while being “negative” for all remaining SH3 probes. For example, the
ENSSVVIPPPDYLECLSM peptide from IRTKS, which exclusively bound Eps8L1 SH3
domain with exceptionally high affinity (> 10 times over average peptide signal),
showed no interaction with any other probed SH3 domain. The Eps8-family SH3
domains are known to preferentially to bind to PxxDY motif-containing ligands
[9]. However, the results of the phage display screen suggested Eps8L3 as a
preferred native interaction partner of IRTKS, which also outcompeted Eps8L1.
Further, the peptide HPLTRVAPQPPGEDDAPY from Efs and
DSLPVAPGRDRPPKQPPT from PHF21B showed selective binding to the second of
three SH3 domains (2/3) of ArgBP2 and CMS SH3 (1/3), respectively. Other
interaction partners which associated with high affinities were the PDZK8
peptide NYKIRFKPFFPYQTLQGF and CIN85 SH3 (1/3) as well as CIN85 peptide
QKPSVPAIPPKKPRPPKT  and  CrkL  and  CMS  SH3  (1/3).  Notably,  14  out  of  65
peptides did not exceed the average binding signals of all peptides for any of the
probed SH3 domains, and only three peptides exhibited negative binding profiles
for all 16 SH3 domains (Table 3 in I).
Comparing the results of the phage display screenings with those from the
peptide array, we found only a moderate correlation. One crucial fact which
needed to be considered when we attempted to compare the results from both
approaches, was that most of the ligand proteins contained at least one peptide
which exhibited a promiscuous SH3-binding character in the peptide array. In
fact, when we removed the six most promiscuous peptides (from ligand proteins
ASAP2, CBLC, PDZK8 and Efs), which led the list of strongest SH3 binding
peptides, only two peptides remained among the upper 10% of peptides which
bound to a certain SH3 domain. Namely the ENSSVVIPPPDYLECLSM peptide from
IRTKS, which was the strongest binding peptide for Eps8L1 SH3 and the third-
best binding peptide of CrkL SH3 (1/2), QKPSVPAIPPKKPRPPKT from CIN85.
We also found that in several cases, peptides of ligand proteins which were
highly selective for certain SH3 domains in the phage display screen did not show
high affinities towards the same SH3 domains in the peptide array. An example
for this scenario was the selection of Src- and Fyn-SH3 domain by PHF21B in the
phage display screen, while the proline-rich peptide of PHF21B clearly bound
with high affinity to CMS-SH3 (1/3) and scored negative for Src and Fyn.
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Due to the excellent reproducibility and overall binding results of the peptide
array, we concluded that the technical quality of the array was good and the
obtained results valid. However, presumably, because the approach addressed
only binding properties of individual peptides, it seemed unable to faithfully
recapitulate the interactions of the corresponding native protein ligands with
their favoured SH3 domains.
4.1.3. Semi-quantitative analysis of SH3 ligand-protein interactions
Due to the limited overlap of the identified strong and selective SH3 interactions
from the phage display screening with the obtained results for the same ligands
from the peptide array, we aimed to study these interactions also in solution.
This approach was further intended to explore our hypothesis that the
interactions, which we identified by phage display screen, were exceptionally
robust.
For this purpose, we developed a semi-quantitative protein pull-down assay in
which we immobilized PP-tagged ligand proteins, transiently expressed from
HEK293T cells. The ligand-coated beads were incubated with solutions of
recombinant expressed and purified SH3 domains at a concentration of 500 nM,
or for Scatchard analysis, with concentration series of the same protein
solutions. The validity and applicability of this semi-quantitative assay were
tested by applying it on the well-characterized interaction between Hck SH3
domain and HIV-1 Nef. The KD-value, which was previously determined for this
interaction using surface plasmon resonance (SPR), was 250nM [121, 122]. The
Scatchard analysis for the obtained data from the Hck-SH3-Nef semi-quantitative
protein pull-down assay resulted in a KD-value of 189 nM. Since both KD-values
were very close, we concluded that our semi-quantitative assay was, despite its
technical limitations, able to produce reliable results for comparably strong SH3-
mediated interactions.
The ligand proteins SH3YL1, SH2B, DENND1A, and PHF21B, were chosen to be
studied in the semi-quantitative protein pull-down assay, together with the SH3
domains of Src, Lyn, CrkL, and Fyn. After incubation of the immobilized ligand
proteins with the recombinant expressed and purified SH3 domains, unbound
proteins were washed off, and the amounts of ligand-associated SH3 domains
were analysed by Western blotting. When comparing the association of the four
SH3 domains to SH3YL1 in the pull-down assay, it was evident that Src-SH3
domain is the preferred target SH3 domain of this ligand. In contrast, the
remaining SH3 domains of Lyn, CrkL and Fyn showed only weak interaction with
SH3YL1 (Figure 3B in I). These results were in line with phage display screening
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results where SH3YL1 bound Src-SH3 domain preferentially (69%). The ligand-
protein SH2B selected Lyn-SH3 exclusively as preferred interaction partner in the
phage display screen. This finding was also true when we examined SH2B in the
pull-down assay, where it preferentially bound to Lyn-SH3 domain and to a lesser
extent the remaining SH3 domains (Figure 3B in I). DENND1A showed in the pull-
down assay a less striking preference towards the four tested SH3 domains.
However, the association of CrkL-SH3 domain was slightly increased compared
to Lyn- and Fyn SH3 domain and even stronger elevated when compared to Src-
SH3 domain (Figure 3D in I). Similarly, DENND1A selected CrkL-SH3 domain as
the preferred binder (71%) in the phage display screen. It is important to note
that none of the DENND1A peptides showed even intermediate binding towards
CrkL-SH3 domain in the peptide array, underlining the striking overlap of the pull-
down assay with the phage display results for native DENND1A. Inline, also
PHF21B preferentially associated with the same SH3 domains in the pull-down
assay as in the phage display screen, namely Src- and Fyn-SH3 (Src- and Fyn-SH3
shared  43%  of  selected  clones,  Figure  3E  in I). In summary, the results we
obtained from the pull-down assay and the phage display screen, in which we
used the full-length, native ligands, showed a good correlation. In contrast, when
the pull-down assay results were compared to the peptide array data, only very
few overlap could be seen, and in some cases (e.g. PHF21B) the preferred SH3
domains of the isolated peptides were completely different from those selected
by the native ligands.
To investigate the affinities underlying the strong and selective SH3 domain-
ligand interactions, which were identified by phage display and further
supported by the pull-down assay, we applied the same type of semi-
quantitative pull-down assay for selected interaction pairs as described for the
estimation of the KD-value of Hck-Nef interaction. The first interaction pair we
studied, was HCLS1 and Lyn-SH3 domain. In the phage display screen, Lyn-SH3
domain was exclusively selected by HCLS1, implying a high affinity for this
interaction. In fact, when we quantified the Western blotting signals of HCLS1-
associated Lyn-SH3 domain from incubations with differently concentrated
solutions  of  the  SH3  domain  and  examined  them  by  Scatchard  analysis,  a
submicromolar KD-value of 746 nM was estimated. Based on the results from the
pull-down assay, the interaction between SH3YL1 and Src-SH3 domain appeared
to be of especially robust nature (Figure 3B in I) and was thereby of particular
interest for evaluation using this approach. Quantification and analysis of the
Src-SH3 domain signals, resulting from the semi-quantitative pull-down assay,
proved the hypothesized strong affinity of this interaction by revealing a KD-value
estimate of 187 nM. In contrast, when we examined with the same method the
interaction between HCLS1 and Fyn-SH3 (which showed either little or no
55
association in the pull-down assay and phage-display screen, respectively), a KD-
value of 7 µM was observed- indicating a significantly reduced affinity for this
interaction.
In summary, the data from this semi-quantitative pull-down assay recapitulated
and thereby supported convincingly the results we retrieved from the phage-
display affinity screens. Furthermore, this correlation promotes the phage-
display affinity screen as a reliable tool to uncover novel high-affinity SH3
domain-mediated interactions. Also, the results implicate that screening
approaches using short linear peptides were unable to recapitulate such specific
and strong interactions.
4.2. Reorganization of PI3K signalling complex by Crk(L)-binding
competent NS1 proteins (II)
4.2.1. Binding of Crk adaptor family proteins to NS1
As identified in the previous study by Heikkinen and colleagues [33], IAV NS1
proteins which contain a C-terminally located class II SH3-binding motif, interact
with cellular CrkII and CrkL proteins and as a consequence potentiate PI3K
signalling. CrkII and CrkL are encoded by two different genes. The gene from
which CrkII is expressed encodes additionally for a shorter form of the protein-
CrkI, which is generated by alternative RNA splicing [55]. This 28 kDa long
polypeptide contains, similar to CrkII and CrkL, the N-terminal SH2 and SH3
domain but lacks the second, C-terminal SH3 domain (Fig. 1A in II). To investigate
whether also CrkI binds to SH3 binding competent NS1 proteins and how strong
this potential interaction is compared to the already known ones of CrkII and
CrkL and NS1, we co-transfected PP-tagged Crk proteins together with the SH3
binding competent NS1 protein from IVA strain
A/Mallard/Netherlands/12/2000/H7N3 (from here on referred as “Mallard
NS1”) and performed protein pull-down experiments. To confirm an SH3 binding
mediated interaction, we extended the experiment by also including SH3 binding
deficient NS1 proteins, in which the critical prolines P212 and P215 were
substituted by alanines “NS1-AxxA”. The analysis of the pull-down experiments
by SDS-PAGE and Western blotting showed clearly a comparable association
between all three Crk proteins and Mallard NS1. The absence of co-precipitated
Mallard NS1-AxxA protein confirmed the SH3 domain-mediated binding as the
driving force of this interaction (Fig. 1B in II).
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4.2.2. Individual contributions of NS1-p85β and NS1-Crk(L) interactions to
activation of PI3K signalling
It was known that both interactions- NS1-p85β [123] and NS1-Crk(L) [33]
promote PI3K activation, yet, the question of individual contributions of the
interactions and their possible mechanistic relation regarding PI3K activation
remained. Hale and colleagues identified a tyrosine at position 89 in NS1 as
critical for binding to the PI3K regulatory subunit p85β [123]. As reported in [33]
and mentioned above, the enhanced PI3K activation by avian and some human
IAV NS1 proteins depends on a functional Crk(L)-SH3 binding motif. To answer
the question of relative impact and a mutual functional relation of the two
binding sites of NS1 in PI3K activation, we analysed phosphorylation levels of the
PI3K substrate Akt in cells transiently expressing either control plasmid only,
wildtype Mallard NS1, the Crk(L) binding deficient Mallard NS1-AxxA and the
p85β binding deficient Mallard NS1-Y89F (tyrosine 89 was substituted by
phenylalanine). In line with previous results from Heikkinen and colleagues, the
obtained phospho-Akt levels in cells expressing NS1-AxxA clearly showed a
reduction in PI3K activation compared to wildtype NS1 expressing cells.
However, only the NS1-Y89F variant was entirely incapable of activating PI3K
signalling (Fig. 2A in II), promoting the conclusion that NS1-Crk(L) interaction
enhances PI3K activation, but this event was entirely dependent on the NS1-
p85β interaction.
4.2.3. NS1 reorganizes the host cell Crk(L)-PI3K complex
SH3 binding-competent NS1 proteins outcompete p85β from binding to Crk(L)
In addition to the already described NS1-Crk(L) and NS1- p85β interactions, Crk
proteins have also been reported to interact with p85 [56, 124]. Interestingly,
Crk proteins bind via the same N-terminal SH3 domain to NS1 and p85. To
investigate the effect of NS1 proteins with different Crk(L)/p85β binding
capacities on a potentially pre-existing Crk(L)-p85β complex, we performed
immunoprecipitation experiments from either untransfected cells or cells
transiently expressing the different NS1 variants. When precipitating
endogenous CrkL from cells, p85β was readily co-precipitated when NS1 was
absent. The presence of either wildtype Mallard NS1 (Crk[L] binding competent)
or Mallard NS1-AxxA (Crk[L] binding deficient) did not show substantial effects
on the Crk(L)-p85β interaction. Strikingly, when the p85β-binding deficient, but
Crk(L)-binding competent Mallard NS1-Y89F was expressed, a substantial
decrease in Crk(L)-p85β association could be detected (Fig. 2B in II). Considering
that Crk(L) binds p85 and NS1 via its N-terminal SH3 domain, the result indicated
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that NS1 outcompeted p85β from binding to Crk(L), most likely as a result of a
higher affinity of NS1 PxxP motif towards the Crk(L) SH3 domain.
To prove the hypothesis that NS1 can outcompete p85β from binding to Crk(L),
recombinantly expressed and purified GST-NS1-Y89F protein was added in a
series of increasing amounts to lysates of cells transiently co-expressing CrkL and
p85β. The association of CrkL and p85β was evaluated by Western blotting
signals of CrkL-co-immunoprecipitated p85β. The obtained results clearly
showed that increasing amounts of added GST-NS1-Y89F displaced p85β from
binding to CrkL in a dose-dependent manner. Strikingly, when the CrkL binding-
deficient variant GST-NS1-AxxA was used in the same experimental setting, no
changes in p85β-CrkL association could be observed (Fig. 2C in II). In an additional
experiment where an NS1 binding-deficient variant of p85β (V573M) and
wildtype GST-NS1 were used, we acquired similar results to those obtained for
wildtype p85β and GST-NS1-Y89F, further supporting the initial hypothesis
(Supplementary fig. 1 in II).
Formation of a trimeric complex consisting of NS1, Crk(L) and p85β
Combining the results from the earlier described co-precipitation experiments
(Fig. 1B, 2B & 2C in II) with pre-existing information on observed interactions
between the studied proteins NS1, Crk(L) and p85β, the formation of a trimeric
complex upon NS1 expression involving all three proteins, became evident.
However, the question remained, why p85β was detected in CrkL-
immunoprecipitates, regardless of whether NS1 was capable of binding CrkL and
thereby displacing p85β. A possible answer to this question was the formation
of two distinct trimeric complexes, whose architecture depend on the SH3
binding  capacity  of  NS1  (Fig.  3B  in II). Due to the ability of wildtype NS1 to
outcompete p85β from binding to CrkL and its direct interaction with p85β, the
association of p85β to CrkL in the presence of wildtype NS1 was most likely
indirect, with NS1 functioning as bridging factor (Fig. 3B in II, “Complex I”). In
contrast, the observed association of p85β with CrkL in the presence of NS1-AxxA
(Fig.  2B in II) was presumably direct, since NS1-AxxA was incapable of binding
CrkL. We hypothesized that in this scenario a second type of trimeric complex
(Fig. 3B in II, “Complex II”) formed, where p85β was instead of NS1 the bridging
factor. In that case, we needed to answer the question of why we were
previously unable to detect NS1-AxxA when immunoprecipitating CrkL. We
considered either the moderate affinity of p85β-CrkL interaction or the
comparably limited availability of endogenous p85β as explanations for NS1-
AxxA being undetectable from a presumably CrkL-immunoprecipitated
“Complex II”. Either way, if our assumptions were correct, co-expression of NS1-
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AxxA together with increasing amounts of p85β should facilitate the association
of CrkL and NS1-AxxA, despite the incapacity of NS1-AxxA binding CrkL directly.
As predicted, the amounts of NS1-AxxA co-immunoprecipitated with CrkL
increased with the amount of co-transfected p85β in a dose-dependent manner
(Fig.  4A  in II). In contrast, the ectopic expression of p85β did no effect CrkL-
wildtype NS1 interaction, which was already detectable when only endogenous
p85β was present.
To extend these findings on naturally occurring SH3 binding-deficient NS1
proteins, the same experimental setup was applied using NS1 proteins from
influenza strains A/Udorn/72 and A/WSN/33. In line with the previous results,
also the amount of naturally SH3 binding-deficient NS1 proteins increased in
CrkL-immunoprecipitates with increasing amounts of co-expressed p85β (Fig. 4B
in II). Notably, when a Crk(L)-binding deficient variant of p85β (P294A, P297A)
was co-expressed instead, only wildtype NS1 could be detected from CrkL-
immunoprecipitates, but none of the Crk(L)-binding deficient NS1 proteins (Fig.
4B in II, right panel). Conclusively, the presented data strongly supported the
existence of two distinct trimeric Crk(L)-NS1-p85β complexes, which formed
either in the presence of SH3-binding competent (Complex I) or SH3-binding
deficient NS1 proteins (Complex II). The recruitment of CrkL to “Complex I” via
NS1 seemed to be more effective than to “Complex II” via p85β.
SH3 binding capacity of NS1 determines the architecture of the trimeric NS1-
Crk(L)-p85β complex
To investigate the formation of the two trimeric complexes in more detail,
interaction studies were performed from cells transiently expressing CrkL,
Mallard NS1 and p85β or their binding-deficient variants (NS1-AxxA, NS1-Y89F,
p85β (P294A,  P297A)  and  p85β (V573M)  in  all  applicable  combinations.  The
putatively formed complexes were captured by either immunoprecipitation of
CrkL or p85β. The results obtained for the CrkL-immunoprecipitated complexes
when co-expressing p85β wildtype together with a control plasmid, NS1, NS1-
AxxA or NS1-Y89F were as expected similar to those presented in Fig.  2B in II.
P85β wildtype could be readily detected from the CrkL-immunoprecipitates of
all samples in comparable amounts, except in the presence of NS1-Y89F, which
dramatically reduced p85β association. All transfected NS1 proteins were
present in the analysed immunoprecipitates (Fig. 5 panel II, lanes 2 to 5). When
the Crk(L) binding-deficient p85β variant (P294A, P297A) was co-expressed, only
the NS1 proteins which directly bound to Crk proteins, wildtype NS1 and NS1-
Y89F, could be co-precipitated. As expected, p85β variant (P294A, P297A) was
only detected from complexes containing wildtype NS1, which in this case
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mediated the interaction. NS1-AxxA was absent from the CrkL-
immunoprecipitates when p85β (P294A, P297A) was co-expressed (Fig. 5 panel
II  & III,  lanes  7  to  9  in II). The ability of p85β in binding NS1 (V573M) had, as
predicted, no effect on the CrkL-p85β (V573M) interaction when either no, or
the SH3 binding-deficient NS1-AxxA was co-expressed. Since wildtype- and the
Y89F variant of NS1 were able to outcompete p85β (V573M) from CrkL-binding,
but unable to directly bind it, a substantial reduction of p85β (V573M) co-
immunoprecipitated with CrkL was observed (Fig. 5 panel II, lanes 10 to 13).
Strikingly, when p85β and p85β (P294A, P297A) were precipitated in an identical
experimental setting, only wildtype NS1, which was capable of binding CrkL and
p85β simultaneously, was causing an increased association of CrkL and p85β.
However, when the NS1 binding-deficient p85β (V573M) was precipitated, no
increase of associated CrkL could be detected, since NS1 could not recruit p85β
(V573M) to "Complex I" (Fig. 5 panel VI, lanes 3, 7 & 10).
Taken together, the presented results strongly supported our hypothesis of two
trimeric complexes, each consisting of Crk(L), p85β and NS1, where either in the
presence of SH3 binding-competent NS1 proteins “Complex I” with NS1 as
bridging factor was assembled or, in the case of SH3 binding-deficient NS1
protein expression, “Complex II” with p85β as connecting element formed.
To rule out that the trimeric complex assembly depended on additional cellular
proteins, wildtype p85β and p85β (P294A, P297A) variant as well as wildtype NS1
and NS1-AxxA and a fragment of CrkL, containing the N-terminal SH3 domain,
were recombinantly expressed and purified. After combining the proteins, p85β
or p85β (P294A, P297A) were precipitated and analysed for co-precipitated
proteins. All three proteins could be detected from the immunoprecipitates
when wildtype NS1 was co-expressed, allowing the formation of “Complex I”
with NS1 functioning as bridging factor (Supplementary Fig. 2A, lane 2 & 8 in II).
Also, the formation of “Complex II”, where p85β was the connecting partner, was
observed when NS1-AxxA was co-expressed with wildtype p85β and the CrkL
fragment. In line with the previous results, the formation of “Complex II” was not
possible when the CrkL binding deficient p85β (P294A, P297A) was co-expressed
(Supplementary Fig. 2A, lane 5 & 10 in II).
4.2.4. Effect of the trimeric NS1-Crk(L)-p85β complexes on PI3K signalling
Assuming that enhanced PI3K signalling caused by SH3 binding-competent NS1
proteins is due to increased efficacy in recruiting Crk(L) proteins to NS1-p85β
complexes, promoting the intracellular availability of Crk(L) proteins should
enhance PI3K activation in the presence of SH3 binding-deficient NS1 proteins.
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Indeed, ectopic expression of CrkL increased phospho-Akt levels when NS1-AxxA
or A/Udorn NS1 was co-expressed but had only a minor effect in the presence of
wildtype NS1 (Fig. 6A &B in II).
Due to the involvement of c-Abl in NS1-SH3 binding [125] and p85β
phosphorylation [126], the role of c-Abl in wildtype NS1 mediated activation of
PI3K was examined by inhibiting c-Abl with Imatinib. No changes in PI3K
activation could be observed (Supplementary Fig. 3 in II), which led to the
conclusion that c-Abl was not involved in the discussed signalling activation.
4.3.  MCV MC159 suppresses cellular autophagy via SH3 domain-
mediated binding to SH3BP4 (III)
Similar to avian and Spanish flu influenza A NS1 proteins, MC159 protein of MCV
was identified as potential SH3 domain interaction partner by scanning viral
proteins from the Swiss-Prot/TrEMBL database with the ScanProsite search tool.
Using this method, we discovered two consensus SH3-binding motifs in MC159.
A class I consensus motif located in the N-terminus and a class II consensus motif
embedded in the C-terminal proximity of the protein. As introduced earlier,
MC159 belongs to the FLIP protein family and thereby contains two DEDs. The
identified N-terminal class I SH3 binding motif overlaps partly with the a0- and
the a1-helix of the DED1. In contrast, the class II motif locates outside of the DED-
region, but proximal to two TRAF binding motifs (Fig. 1 in III).
4.3.1. Phage display on MC159 and identification of cellular SH3 binding
partners
To investigate the SH3 binding capacity of MC159 and to identify potential SH3
binding partners, MC159 was expressed and purified from mammalian 293T cells
as PP-fusion protein and immobilized to streptavidin-coated magnetic beads. We
subjected immobilized MC159 as well as a PP-tagged control to affinity
screenings using our virtually complete human SH3 phage display library [127].
Already after a single round of affinity selection, MC159 conjugated beads
showed a substantial enrichment of phages (> 20 fold) compared to control
beads (Fig. 2A in III), suggesting MC159 as a potent SH3 ligand. Sequencing
analysis of the MC159 selected phages, identified the SH3 domain of human SH3
binding protein 4 (SH3BP4) as the highly selected binder. In three individual
phage library screening experiments, SH3BP4 SH3 domain represented 80 to
100% of the sequenced phage clones (Fig. 2 in III).
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To investigate the impact of the two consensus SH3 binding motifs of MC159 on
SH3BP4 SH3 domain binding, we generated different variants of MC159, being
defective either in one or both motifs. For this purpose, both critical prolines of
class I and II motifs were substituted by alanines using site-directed mutagenesis
(PxxP to AxxA) (Fig. 1 in III).  The so generated MC159 variants were tested as
affinity ligands in SH3 phage display screenings, using an identical experimental
set-up. While functional abrogation of the C-terminal PxxP motif [MC159AXXA(C)]
had no effect on SH3 phage enrichment, disruption of the N-terminal SH3-
binding motif alone [MC159AXXA(N)] or together with a non-functional C-terminal
PxxP motif [MC159AXXA(N+C)], efficiently inhibited the enrichment of phages over
control (Fig. 2 in III). Consequently, we concluded that the N-terminal class I SH3-
binding motif of MC159 promotes the binding to SH3BP4-SH3 domain. In
contrast, the C-terminal motif could not be demonstrated as a functional SH3
binding site, despite resembling a perfect class II consensus motif.
Since the SH3 domain of SH3BP4 was dominating the affinity selection of the
class I motif profoundly, we considered the existence of other SH3 domains
binding to MC159, which were possibly masked by the avid binding of SH3BP4
SH3 domain to MC159. Therefore, we generated a phage library which was
depleted of the SH3BP4 SH3 domain and repeated the phage affinity screen.
However, no enrichment of wildtype MC159 over control beads was observed
when using the depleted phage library, indicating SH3BP4 as unique selective
MC159 binder among human SH3 domains. Conclusively, the results from the
phage screen experiments indicate the SH3 domain of SH3BP4 as the only
preferred binder of the MC159 class I SH3 binding motif.
4.3.2. Association of full-length SH3BP4 to MC159 in cells
To validate and extend our findings from the phage display experiments, we
transiently expressed a Myc-tagged version of the full-length SH3BP4 together
with PP-tagged MC159 proteins in mammalian 293T cells. Streptavidin-coated
magnetic beads were used to precipitate PP-MC159 protein complexes, which
were subsequently separated and analysed by SDS-PAGE and Western blotting.
Full-length SH3BP4 could be readily co-precipitated with MC159 proteins with an
intact N-terminal PxxP motif (Fig. 3A, lanes 2 & 4 in III). In line with the results
obtained from the phage screening experiments, disrupting the N-terminal PxxP
motif abrogated the interaction almost entirely, while mutation of the C-
terminal PxxP motif had no effect on SH3BP4 co-precipitating with MC159 (Fig.
3A,  lanes  3  &  5  in III). Notably, a residual binding of SH3BP4 to MC159 was
observed when precipitating MC159AXXA(N) or MC159AXXA(N+C) (Fig. 3A, lanes 2 & 4
in III). Since the mock-protein pull-down was completely devoid of SH3BP4, the
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residual association of SH3BP4 to MC159 suggested additional weak interactions
between the proteins.
To exclude that the observed interaction between the MC159 proteins and
SH3BP4 was solely a result of protein over-expression, we repeated the
experiment expressing only MC159 proteins transiently. Analysis of the
precipitated protein complexes showed a similar interaction pattern of MC159
proteins with endogenous SH3BP4.
4.3.3. Impact of SH3BP4 binding capacity on cellular functions of MC159
The inhibition of FAS and TNFR1 death receptor-mediated NF-κB activation and
apoptosis induction are well-established functions of MC159 [64, 74, 75]. We,
therefore, investigated the role of MC159-SH3BP4 binding in the context of these
functions.
To investigate whether binding of MC159 to SH3BP4 had an impact on TNF-
mediated NF-κB activation, we tested wildtype and SH3-binding deficient MC159
in an NF-κB-luciferase reporter assay [82]. In line with previous reports [80-82],
expression of wildtype MC159 together with the NF-κB-luciferase reporter
plasmid showed a slight increase of NF-κB constitutive activity and effectively
blocked TNF-mediated NF-κB activation (Fig. 4 in III). However, when
MC159AXXA(N) was tested in the same experimental setting, no significant
difference in modulating NF-κB activity could be observed, suggesting MC159-
SH3-binding not being relevant for this function (Fig.4 in III)
To study the inhibition of FAS and TFNR1-induced apoptosis by MC159, we
transiently expressed either control plasmid, wildtype MC159 or MC159AXXA(N) in
cycloheximide-sensitized HeLa cells, which were 24 hours post-transfection
either treated with 10 ng/ml TNF or left untreated. We monitored the Induction
of apoptosis by analysing the proteolytic cleavage of caspase-8 and -3 by
Western blotting. The reduction of caspase-3 and the appearance of cleaved
caspase-8 were detected and quantified. While the quantified signals readily
proved the previously reported anti-apoptotic function of wildtype MC159, its
SH3 binding capacity did not show any significant effects on this activity, since
MC159AXXA(N) inhibited TNF-α induced apoptosis as effectively as wildtype MC159
(Fig. 5 in III).
MC159 and other FLIPs have been reported as negative regulators of cellular
autophagy [71]. In contrast, SH3BP4 was independently found to possess pro-
autophagic functions [91]. Therefore, we investigated the effects of wildtype
MC159 and the SH3BP4 binding-deficient MC159AXXA(N) on cellular autophagy. For
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this purpose, we used a previously characterized MCF7-derived macroautophagy
reporter cell line, which stably expressed enhanced green fluorescent protein-
conjugated LC3 (MCF-7/LC3-EGFP) [128] and transduced them with lentiviral
vectors encoding for wildtype MC159- or MC159AXXA(N)-mCherry fusion proteins.
Comparable expression patterns and levels could be observed for stably
expressing wildtype MC159 and MC159AXXA(N)-mCherry MCF-7/LC3-EGFP cells
(Fig.  6A to C in III). Importantly, no differences in average number and size of
autophagosomes were observed between the two MCF-7/LC3-EGFP cell lines
stably expressing MC159 proteins and the parental cell line under standard cell
culture conditions (Fig. 6A in III).
When amino acids, together with other nutrients, were withdrawn from the
parental MCF-7/LC3-EGFP cells for 6 hours, a significant increase in the number
of autophagosomes could be detected (Fig. 6B in III). In line with the study from
Lee and colleagues [71], the MCF-7/LC3-EGFP cells expressing wildtype MC159
showed a less dramatic increase in the number of autophagosomes in response
to nutrient starvation (Fig. 6B in III). Remarkably, in cells which stably expressed
the SH3BP4 binding-deficient MC159AXXA(N), a robust induction of autophagy,
similar as seen in the parental cells, could be observed (Fig. 6B in III). The Image
analysis and quantification of autophagosomes were done using Imaris Software
9.2 from Bitplane, from three independent experiments (Fig. 6E in III).
To confirm our findings, we carried out an alternative approach addressing
cellular autophagic activity, independent of fluorescent imaging. For this
purpose, we analysed intracellular p62 levels by Western blotting, which we
obtained from lysates of the same MCF-7/LC3-EGFP parental and stably
expressing MC159 cell lines. P62 is a selective autophagy receptor, which delivers
its cargo via binding to LC3 to maturing autophagosomes. In the course of
autophagic degradation of the delivered cargo, p62 becomes degraded itself and
thereby functions as an informative reporter of cellular autophagy [129, 130]. As
expected, subjecting the parental cell line to 6 hours nutrient starvation
provoked a substantial reduction of detectable p62 protein levels (Fig. 6D in III),
indicating a robust induction of autophagy in these cells. In agreement with the
results obtained from the imaging analysis, cells which stably expressed wildtype
MC159 showed, compared to parental cells, a less dramatic fold reduction of p62
levels. This finding supported the previous observation of wildtype MC159 being
a negative modulator of autophagy (Fig. 6B & E in III). No anti-autophagic activity
was observed in SH3BP4-binding deficient MC159AXXA(N) expressing cells,
indicated by the profound reduction of p62 protein level (Fig. 6D in III).
To prove the direct, functional involvement of SH3BP4 in the observed MC159-
SH3BP4 binding-correlated autophagy inhibition, we generated an SH3BP4
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knock-out version of the MCF-7/LC3-EGFP cell line by using CRISPR/Cas9
technology. From this knock-out cell line, we generated lentivirally transduced
populations, stably expressing either wildtype MC159 or MC159AXXA(N). The
absence of SH3BP4, as well as the equal expression of MC159 proteins from the
generated cell lines, was confirmed by Western blotting (Fig. 6C in III). The
analysis and quantification of autophagosomes were carried out as described for
the SH3BP4 expressing MCF-7/LC3-EGFP cells. We observed no changes in the
basal number of autophagosomes under standard cell culture conditions when
SH3BP4 was absent. However, under starvation conditions, autophagy was
slightly lessened, which could be explained by the previously identified role of
SH3BP4 as a negative regulator of mTORC1 signalling [91]. Strikingly, unlike in
SH3BP4 expressing cells, wildtype MC159 was incapable of counteracting
starvation-induced autophagy in cells being depleted of SH3BP4. Inline, the
previously observed difference between wildtype MC159 and MC159AXXA(N),
functioning as an autophagy inhibitor, was completely absent in SH3BP4 knock-
out cells (Fig. 6E in III).
Based on the aforementioned data, we concluded that the ability of MCV MC159
protein to counteract starvation-induced autophagy depends on its SH3 domain-
mediated interaction with host cell SH3BP4.
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5. Discussion
Since the discovery of the SH3 protein domain almost 30 years ago [25], the
exploration and understanding of SH3-mediated and -related interactions, as
well as their effects on cellular signalling, has greatly advanced our
understanding of cellular biology, disease development, and also exploration of
the host cell machinery by pathogens. Phage display affinity screens have
throughout the years strongly contributed in shedding light into the cellular SH3-
interaction network by uncovering novel interactions and as important, revealed
how numerous pathogens hijack this network. The discussed results contribute
essential and novel aspects of phage display-based identification of SH3 domain-
mediated interactions as well as their functional consequences.
A major objective of study I was the systematic exploration and mapping of the
human “SH3 interactome”. Specifically, we aimed for the identification of
exceptionally strong and selective SH3 domain-mediated interactions. Following
this approach, we intended to understand how frequently SH3 domains play a
dominant role in protein interaction partnerships and to discover novel
interactions as leads for new studies addressing cell signalling networks.
When screening for novel protein interactions, phage-display technology offers
a profound advantage over other screening methods, which is the use of full-
length ligand proteins. This feature provides all physiological contacts/ surfaces
which are possibly needed for a specific SH3 domain interaction. To ensure the
native folding and correct post-translational modification of the potential SH3
ligand proteins, we expressed the selected polypeptides in mammalian HEK293T
cells. Using this approach, we were able to express proteins from 324 of the 449
ORFs, which were previously identified as potential SH3 ligands from the human
ORFeome library 3.1 by bioinformatical screenings.
Previous studies successfully used the SH3 phage library to identify novel
interaction partners for cellular and pathogen-originated ligand proteins and
revealed this method as an efficient tool, especially to discover high-affinity SH3
domain-mediated interactions [16, 29, 127, 131, 132]. In this context, a
convincing number of identified interactions was subsequently biochemically
and functionally verified, supporting the physiological relevance of interactions
identified by phage-display screens. One important factor that clearly supports
the high success rate in predicting physiologically meaningful SH3-mediated
interactions is the feature of the method to uncover high-affinity interactions.
An illustrating example is the discovery of the HIV-1 Nef protein interaction with
Hck- and Lyn-SH3 domain by phage-display affinity screen [127]. Both
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interactions exhibit affinities in the submicromolar range [Nef-Hck-SH3 KD = 250
nM [121]]. By contrast, the SH3 domains of Lck and Fyn, which have been
previously characterized as functional Nef-interaction partners by isothermal
titration calorimetry [133], could not be identified by phage-display affinity
screening, most likely due to their lower affinities towards Nef (Lyn-SH3 = 10.6
μm  and  Fyn-SH3  =  15.8  μm  [133].  This  circumstance  exemplifies  a  technical
limitation of the SH3 phage-display in detecting moderate or low-affinity
interactions, which nevertheless exhibit biological relevance. Since most SH3-
mediated interactions are believed to be of rather transient and thereby low-
range affinity nature, it would be certainly of interest to consider measures,
which improve the phage-display towards the detection of lower affinity range
SH3-mediated interactions. Increasing the SH3-phage library titer or depletion of
highly dominant binders from the library could serve as such measures. On the
other hand, detecting only high-affinity interactions decreases the false-positive
discovery rate significantly, supporting the presented, novel SH3 domain-
mediated interactions as likely being biologically relevant.
However, given that out of 324 potential SH3-ligands, only 19 (5.6%) showed
defined preferences towards specific SH3 domains, the overall appearance of
such strong and selective interactions seems to be rather rare in the human SH3-
interaction landscape. It should be noted though, that in total 44 (13.6%) of the
324 ligand proteins showed substantial enrichment of phages over control,
suggesting them as functional SH3-ligands. Nevertheless, the remaining 86% of
the tested potential SH3-ligands failed to identify as such in this approach. These
findings reflect the common understanding that the majority of SH3-mediated
interactions are transient and exhibit rather low affinities [134]. Accordingly,
novel functional or other non-affinity-based screens should be developed in
order to identify such weak but important interactions systematically.
A crucial fact which should not be missed when evaluating SH3 domain-mediated
interactions is that proteins and especially proteins which contain modular
domains- such as the SH3 domain, mainly exist as components of protein
complexes. In this environment, additional interaction surfaces, either between
the SH3 interaction partners or provided by other factors of the complex, can
significantly increase the overall affinity of these interactions. Since we used
isolated and purified ligands in the phage-display screening, SH3-mediated
interactions, which depend on such additional contacts, would clearly be missed.
The same is true for interactions which rely on the specific localization to certain
cellular compartments or active co-localization of the interaction partners. In this
context should be further considered that some of the SH3-binding motifs in the
screened 324 ligand-proteins are eventually non-accessible and only get exposed
by conformational changes of the ligand (e.g. upon its activation by cellular
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signalling cascades, alteration in phosphorylation patterns or other post-
translational modifications).
Consideration of these aspects sheds new light onto the identified strong and
selective SH3 domain-mediated interactions since the two interaction partners
alone can establish such highly affine and specific interactions in a cell-free
environment. This is further supported by the results we obtained from the semi-
quantitative pull-down assay, which suggest for these interactions KD values in a
submicromolar range. Furthermore, they demonstrate that the studied ligand
proteins bind their preferred SH3 domain with high selectivity and discriminate
even among closely related SH3 domains. Thereby, it is reasonable to assume
that highly affine SH3 domain interactions can act as driving forces in defining
protein-protein interaction partnerships, also in the context of multiprotein
complex assembly. There are indeed examples where the structural analysis of
such complexes has proven the previous assumptions, for example, p47hox and
p67hox-SH3 [135], PAK and βPIX-SH3 [136], SLP-76 and GADS-SH3 [137] and
others. Typical for these interactions are additional areas/ determinants in the
ligand-proteins, which increase the overall affinity. These determinants either
surround the core PxxP SH3-binding motif, but can also be the result of more
complex structural features of the ligand-protein.
The results from the peptide array support the assumption that the high-affinity
SH3-mediated interactions, which were identified in our study by phage-display,
most likely rely also on such extended contacts. Only a few of the SH3-phage
library identified interactions could be recapitulated by the results from the 65
isolated peptides used in the array and vice versa. However, a better overlap of
the phage-display and peptide-array results can be seen, when we look at
relative binding preferences of the peptides towards specific SH3 domains rather
than absolute binding strengths. However, our results suggest that for the
identification of SH3-mediated interactions, the use of large-scale peptide-array
screens is, due to the peptides’ lack of accessory interacting determinants, of
limited applicability.
When considering the physiological importance of the newly identified high-
affinity interactions from this study, it is essential to note that the strong
association of two proteins does not equal a significant biological relevance per
se. However, it is quite likely to often be so, since SH3-mediated interactions
which were previously identified by our laboratory using this phage-display
screening method [127], were identified independently by others [138, 139].
That supports our presented dataset being a valuable and useful resource for
further exploration of biological consequences of these newly identified SH3
domain-mediated interactions.
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A recent investigation, led by Sachdev Sidhu [12] used a combined approach of
random peptide library phage display and deep sequencing. Using this methods,
they identified several novel non-canonical SH3-binding motifs. This broad, high-
throughput screening approach generated an individual peptide binding-profile
for 115 SH3 domains from 89 proteins. It revealed that about half of the
examined 115 SH3 domains prefer (at least in this in vitro setting) so far
undescribed non-canonical SH3-binding sites. In addition to the well-established
class I and II SH3-binding consensus motifs, the study proposes seven new
binding motif classes. While the “classes III to VIII” represent potentially novel
consensus sequences, “class IX” is a summary of peptide sequences preferred by
35 individual SH3 domains. It would be of interest to extend our biostatistical
screening of the human ORFeome library for potential SH3-ligands by these
newly identified SH3-binding sequences. Excluding the PxxDY motif (preferred by
Eps8(L)1-SH3 domain), which was already included in our initial bioinformatic
screen. Of note, this peptide-phage display screen has similar limitations as our
peptide-array. The potential screened SH3 domain interaction partners are
solely 12 amino acid long peptides, and potentially important additional
interaction surfaces from the full-length ligand are missing.  Therefore, it is
reasonable to assume that despite the comprehensive analysis of the human SH3
interactome by us and others [12], there are most likely several SH3 domain
interaction motifs and modes, which have yet to be identified.
Interestingly, the described phenomenon of high-affinity SH3-mediated
interactions is frequently described for viral ligand proteins. In the case of HIV-1
Nef binding to Hck-SH3, the exceptional high affinity of the interaction enables
the viral protein to dictate the activation state of the non-receptor tyrosine
kinase Hck and thereby enhances its kinase activity [140]. Another illustrating
example is the SH3-mediated binding of Influenza A virus NS1 protein to Crk
adaptor proteins [33], which forces the reorganization of the complex consisting
of Crk(L) and P85β towards a trimeric complex in which NS1 is the connecting
factor (study II). Furthermore, this interaction can drive the re-localization of
Crk(L) from the cytoplasm to the nucleus, which causes changes in the
phosphorylation profile of nuclear proteins [141].
Strikingly, and in line with our hypothesis, a very recent study obtained by
monitoring the fluorescence intensity change upon complexation, a KD-value for
the NS1 proline-rich motif (PRM)-CrkII-SH3 interaction of 6 nM [142]. This would
imply this interaction is about 40 times stronger than the one between Nef and
Hck-SH3 and more affine than any other known SH3-mediated interaction. In
studies which were previously undertaken in our laboratory, we were able to
directly compare HIV-1 Nef and Influenza A NS1 SH3-binding by phage-display
(unpublished data). We found Nef-associated phage-enrichment notably
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increased compared to the enrichment observed for NS1, which is not in
complete agreement with the remarkably low KD-value reported by [142].
Nevertheless, phage-enrichment of NS1 compared to control was significant and
highly selective towards CrkII- and CrkL-SH3, which represented 90% of the
identified clones [33]. Thus, and based on the arguments as we presented in
study I for the newly identified “strong and selective” SH3 domain-mediated
interactions, implying a high affinity (in the submicromolar range) for this
interaction.
 As mentioned above, the highly affine and selective interaction between avian
and Spanish flu Influenza A virus NS1 proteins is driving the reorganization of a
naturally existing complex between Crk(L) proteins and the PI3K regulatory
subunit p85β. This reorganization and the newly formed trimeric complexes, as
well as their functional consequences in PI3K signalling, are subject of study II.
This investigation was initiated after the discovery in our laboratory that avian
and Spanish flu Influenza A virus NS1 proteins bind highly selectively to Crk
adaptor proteins and as a consequence potentiate PI3K signalling compared to
Crk(L)-binding deficient NS1 proteins [33]. To elucidate the mechanism how
Crk(L)-binding NS1 proteins are capable of hyper-activating PI3K signalling was
of particular interest since all three proteins- NS1, Crk(L) and p85β were found
to interact with each other in previous studies. Furthermore, each individual
interaction affected PI3K signalling reportedly [33, 56, 57, 143, 144].
Interestingly, the interaction of Crk proteins with the PI3 kinase regulatory
subunit p85 was reported to be mediated via the N-terminal SH3 domain of
Crk(L) and a proline-rich motif in p85 [57, 126, 143, 145]. Since the same domain
was identified by our laboratory to be responsible for the interaction between
Crk(L) and SH3-binding competent NS1 proteins [33], we developed the working
hypothesis for study II that the viral ligand possibly induces a rearrangement of
the pre-existing protein Crk(L)-p85 complex.
Using mutational analysis, we identified that the direct interaction of NS1 and
p85β, via the critical tyrosine residue in position 89 of NS1, is essential for the
hyper-activation of PI3K signalling by Crk(L)-binding competent NS1 proteins. By
employing numerous variants of the studied interaction partners, we were able
to show that in the case of SH3-binding competent NS1 proteins, the hypnotised
reorganization of the pre-existing Crk(L)-p85 complex takes place. In this newly
formed “Complex I” NS1 acts as a bridging factor between Crk(L) and p85.
Furthermore, we found, that in the presence of SH3-binding deficient NS1
proteins an alternative trimeric complex consisting of Crk(L), p85 and NS1 forms.
However, this “Complex II”, in which p85 functions as the connecting element,
could only be detected when p85 was overexpressed. We observed a clear
correlation between the complex architecture and PI3 kinase activity, whereas
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complex I promoted an increased PI3 kinase activity. Subsequently, we
hypothesized that in the case of complex II, the low abundance of endogenous
p85 as well as its moderate affinity towards Crk(L)-SH3 domain, recruited Crk(L)
less effectively to the complex and thereby less potently activated PI3 kinase. In
favour of this hypothesis, when we overexpressed Crk proteins in cells co-
expressing SH3 binding-deficient deficient NS1 proteins, we observed increased
pAkt levels, comparable to those in cells co-expressing SH3-binding competent
NS1 proteins.
In summary, our findings promote the assumption that the efficacy of Crk protein
recruitment to the trimeric complex is determining the extent of PI3 kinase
activation. How exactly Crk proteins promote PI3 kinase activation in this
context, has still to be elucidated. There are several scenarios imaginable. Since
Crk proteins are prototype adaptor molecules, they harbour in addition to their
SH3 domain(s) an SH2 domain. Consequently, it is a likely scenario that Crk
proteins direct the entire complex by binding to another protein, e.g. via the SH2-
domain, to a certain cellular compartment or site where PI3 kinase can efficiently
be activated or has improved access to its substrates. The findings that the
interaction between Crk proteins and NS1 is highly affine [142] and that NS1 has
recently been found to cause a relocation of Crk proteins from the cytosol to the
nucleus [141], support this hypothesis. Furthermore, there are reported Crk
interaction partners who could function as such docking sites for Crk proteins
and are known to locally promote PI3 kinase activation, namely the focal
adhesion kinase (FAK) [145], p130cas [146] and c-Cbl [147].
Since the basic mechanism of PI3 kinase activation by NS1 proteins is the release
of inhibitory contacts between p85 regulatory- and p110 catalytic PI3 kinase
subunits [144], another reasonable role of Crk(L) in PI3 kinase activation could
be an  additional contribution in destabilizing inhibitory contacts. However, the
highly efficient binding of NS1 to Crk proteins and the subsequently increased
recruitment of the adaptor proteins to the PI3K complex, represents most likely
a key element in avian and Spanish flu NS1 PI3 kinase hyper-activation.
Notably, the same study which recently reported the remarkable KD value for the
NS1 PRM and CrkII-SH3 interaction, identified additional sites, adjacent to the
PxLP core SH3-binding motif in NS1, which significantly contributed to the strong
interaction. Especially the combination of short-range electrostatic interactions
between the NS1 PRM lysine 217 and the specificity area of Crk-SH3 domain
(D147, E149 and D150) as well as the formation of hydrogen bonds between two
NS1 PRM amide backbones (Q218, K219) and Crk-SH3 glutamic acid 166,
promoted the interaction. Furthermore, the overall positive charge of the NS1
PRM establishes long-distance electrostatic interactions, which support the
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observed rapid association of NS1 with Crk proteins [142]. This extended
interaction surface enables NS1 to hijack Crk proteins from their regular cellular
interaction partners and to manipulate further signalling pathways which are
regulated by Crk(L), as we could show in study II.
The functional importance of NS1-Crk(L)-SH3 binding for IAV life-cycle seems to
be, however, strongly strain- and subsequently host-dependent [148]. While the
NS1 SH3-binding motif appears to be important for avian IAV replication in their
natural hosts [125], it does in most cases not provide any benefit when it is
introduced to NS1 proteins which naturally lack the binding site [149]. As
mentioned before, IAV strains which naturally lack Crk(L)-binding ability, are
mainly adapted to humans. While the primary site of replication in the human
host are epithelial cells of the respiratory tract, in birds, IAV replicates in
intestinal epithelial cells. Consequently, the cellular environment in which
human and avian IAV replicate is significantly different, and the need for specific
host-cell factors is likely to differ as well. In this context, intermediate hosts
susceptible to IAV strains of both origins, human and avian, are of particular
interest for host-cell factor requirements of the virus. Hale and colleagues have
tested, whether the introduction of a functional Crk(L)-binding site (E217 to K
mutation) in NS1 enhances viral replication of the 2009 pandemic H1N1 IAV in
human, but also swine cells. The results showed no increase in viral replication
in either cell type [147]. When considering the recent identification of the
adjacent binding sites in the NS1 PRM, that contribute significantly to the affinity
between NS1 and Crk(L)-SH3, one could certainly argue that a single amino acid
change does not create the necessary high affinity. Yet, a single amino acid
change in IAV Udorn NS1 (T215 to proline) created a Crk(L)-SH3 binding site
identical to the one, which exhibited the KD value  of  6  nM  towards  CrkII-SH3
[142]. Another explanation could be that swine tracheal epithelial cells are
physiologically too close to those from humans to show an effect when
introducing the Crk(L)-SH3 binding site into NS1. In recent years, chickens and
their role as a potential intermediate host gained more attention. Like in pigs,
chicken tracheal epithelial cells exhibit sialic acid linked to galactose by α-2,6
linkages (SAα2,6Gal), preferably bound by human IAV and SAα2,3Gal, bound by
avian IAV. Notably, SAα2,6 Gal dominates in the chicken trachea, rendering them
susceptible infection with IAV from both origins [150]. Yet, the physiology of
these cells is avian-like and thereby typical avian IAV host factors like Crk(L) are
likely to be indispensable, eventually also for strains which do not naturally
contain an SH3 binding motif. Consequently, it could be of interest to test human
IAV strains in chickens, which express SH3 binding-competent NS1 proteins.
A recent investigation led by Benjamin G. Hale analysed the evolution of NS1-
p85β binding of human IAV strains, which circulated globally during the last
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century [151]. The experimental results indicate that enhanced binding of NS1
to p85β is advantageous for IAV in competition assays. Their thorough
bioinformatic analysis of over 24000 NS1 sequences also revealed that NS1
variants harbouring residues, which promoted increased p85β binding, occurred
and were maintained in the human population over decades in the 20th century.
However, also NS1 variants with reduced p85β binding capacity appeared and
established in human IAV strains since the end of the 20th century [151]. The
authors propose that a decrease in viral fitness, caused by reduced p85β binding,
could have been compensated by changes in other parts of the virus. Our
findings from study II shows that IAV has also developed other tools, namely the
SH3 domain-mediated binding to Crk proteins, to increase PI3kinase signalling.
Nevertheless, it is crucial to note that the study from Turkington and colleagues
addressed only the correlation between NS1-p85β binding with viral fitness/
survival and not the effect of PI3kinase activation in this context. Another
remarkable finding from the same laboratory is that NS1 proteins from two bat
IAV isolates, are entirely incapable of binding p85β and activating PI3 kinase
[151]. This discovery underlines the extensive adaptation of IAV to their hosts,
and thereby the diversity of the different IAV strains in hijacking host cell
signalling factors and pathways.
The phenomenon of viruses being highly adapted to their host’s cell environment
is a key strategy of viral survival. Since IAV encodes for a relatively small number
of proteins, it is not too surprising that the NS1 protein interacts with and
manipulates host cellular factors in such a versatile way. In contrast, the viral
protein which is subject of study III,  MCV  MC159,  is  part  of  a  large  pox-viral
machinery consisting of 182 proteins. Also, this protein has, similar to IAV NS1,
shown to be a key immuno-evasion factor of the virus. Though, it seems at first
glance somewhat surprising that a single protein is bearing such essential
functions when the virus expresses such a battery of viral proteins. Considering
the life-cycles of IAV and MCV, it becomes more obvious why the latter requires
a complex network of viral factors tightly controlling the host cell. MCV, alike
many large DNA-viruses, establishes long-lasting infections which can persist up
to 4 years [63]. Therefore MCV has developed to be almost invisible to the host
cellular immune system, and this requires tools precisely containing anti-viral
actions  of  the host  [64].  MC159 is  together  with  MC160,  one of  the two viral
FLIPs expressed by MCV. Viral FLIPs and their cellular counterparts are pro-
caspase-like proteins, which function as key regulators of cellular apoptosis [74,
75, 152], and inhibitors of cellular autophagy [71].
Apart from being a key factor in viral immune evasion, MC159 and IAV NS1 have
another feature in common; they both comprise bona fide SH3-binding sites. In
fact, this feature is unique to MC159 among the FLIP family and made it of
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particular interest to our laboratory. Starting our work on MC159, we identified
two SH3-binding consensus motifs, a class I consensus motif in the very N-
terminus of the protein and a class II motif in the C-terminal proximity. However,
we could only identify the N-terminal class I motif as a functional SH3-binding
site using the phage-display affinity screen, which revealed its exclusive binding
to the SH3 domain of cellular SH3BP4. When looking at the second class II motif
in MC159, it is puzzling that no preferred SH3 domain could be identified. The
motif contains, apart from the typical key residues promoting SH3-binding
(PxφPx+), additional flanking residues possibly contributing to higher affinities in
that context [142]. As already discussed in the context of study I, it is important
to keep in mind that the identification of SH3-interaction partners by phage-
display also has limitations. However, selective binding to the SH3 domain of
SH3BP4 could be observed for the N-terminal class I motif, making it the key
determinant of MC159 acting as SH3-ligand. The location of the motif in the viral
protein is, however, unusual. In many viral SH3-ligand proteins the binding sites
are located in unstructured, highly flexible regions, as it is the case in IAV NS1
[33]. In contrast, in MC159 the motif is part of the DED1 helices H0 and H1.
Notably, in the crystal structure of MC159 the key prolines at positions eight and
11 point in opposite directions [72], suggesting a conformational change in
MC159 as either required for prior or happening upon binding of the SH3BP4 SH3
domain. This could also explain the high preference of the motif towards SH3BP4
SH3 domain, despite its classical consensus sequence, indicating the binding site
as rather promiscuous.
At the time, we identified SH3BP4 as an interaction partner of MC159, only
limited information about this cellular protein was available. However, the few
articles which were published suggested the involvement of SH3BP4 in critical
cellular processes. SH3BP4 was found to regulate transferrin receptor
internalization by promoting cargo-specific clathrin-mediated endocytosis [93].
It was also found to be critical for FGF-receptor trafficking after internalization
and subsequent functional events [94]. However, of particular relevance to study
III was the finding that SH3BP4 is involved in the regulation of cellular autophagy.
By directly binding to Rag-GTPases, SH3BP4 prevents their recruitment to
mTORC1 and thereby inhibits amino acid-induced mTORC1 activity. This
consequently induces autophagy and further inhibits cellular growth [91].
Since MC159, among other viral FLIPs, had independently been shown to inhibit
cellular autophagy [71], the effect of MC159 binding to SH3BP4 in the context of
autophagy induction was of particular interest for us. Moreover, the pro-
autophagic activity of SH3BP4 was reported to be dependent on the same SH3
domain, which we found to be responsible for MC159-SH3BP4 interaction [91].
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In fact, our results showed that loss of the functional N-terminal SH3-binding site,
rendered MC159 being incapable of counteracting starvation-induced
autophagy. Furthermore, we found that in cells which were depleted of SH3BP4,
the existence of a functional SH3-binding site became irrelevant, and neither
wildtype nor the AxxA-variant of MC159 could inhibit starvation-induced
autophagy.
When envisioning the mechanism of how MC159 counteracts autophagy by
binding to SH3BP4 SH3 domain, the most obvious scenario would be that MC159
prevents SH3BP4 from binding to Rag-GTPases and thereby supports mTORC1
activity. However, it was shown before that MC159 also counteracts the
mTORC1-inhibitor rapamycin, which acts independently of the Rag-GTPase-
mTORC1 association status [71]. Moreover, the same study identified that viral
and cellular FLIPs inhibit autophagy downstream of mTORC1 by binding the E2-
like enzyme Atg3 and thereby prevent the processing of LC3I to LC3II. However,
it is important to note that a causal relation between vFLIP-Atg3 binding and
autophagy inhibition was only shown for KSHV FLIP K13. In this context, the
authors found the K13 H2 helix of DED1 and H4 helix of DED2 being indispensable
for the reported effect. Despite MC159 reportedly showed an Atg3 interaction
profile similar to KSHV vFLIP, the DED1 of both proteins have considerable
structural differences [72], which makes a direct transfer of functional effects of
KSHV vFLIP on MC159 questionable. Also, considering the mechanistic diversity
in vFLIP-mediated inhibition of death receptor-induced apoptotic signalling [64],
it is reasonable to assume that also in the context of autophagy inhibition,
different  strategies  are  employed.  Since  MCV  encodes  for  a  second  vFLIP,
MC160, it would be informative to test, whether this protein also shows Atg3-
binding activity and inhibitory effects on autophagy. Nevertheless, the
investigation of a possible effect or contribution of MC159-SH3BP4 interaction
on the binding of Atg3 to MC159 should receive further attention.
As discussed, binding of MC159 to SH3BP4 causes possibly conformational
changes in MC159, which could also have consequences on the ability of MC159
binding to other proteins, e.g. Atg3. This suggested conformational change also
allows envisioning so far unconsidered mechanisms of how MC159-SH3BP4
interaction contributes to autophagy inhibition, independent of Rag-GTPases or
Atg3. For example, MC159 harbours a potential so-called LC3-interacting region
(LIR) motif “SRFVEL” starting at position 139 in its second DED [153]. Under
isolated conditions, the DEDs of MC159 adopt a rigid dumbbell-shaped
conformation, in which the valine 142 of the LIR motif is completely buried [72].
If a conformational change in MC159 would release both DEDs from each other,
the motif could become functional. LIR motifs have a fundamental role in
selective autophagy by mediating the binding of autophagy receptors (e.g. p62)
75
to phagophore-anchored Atg8 proteins (e.g. LC3) and thereby allow the delivery
of the receptor-cargo towards autophagosomal degradation [154]. As a result,
binding of MC159 to Atg8 proteins could block the binding of selective autophagy
receptors and their cargo-delivery.
However, of the previously reported MC159 functions we examined in study III,
autophagy remained the only one, on which alteration of MC159-SH3BP4
interaction had a measurable effect. In this context, wildtype and the SH3BP4
binding-deficient AxxA variant showed comparable activities in moderately
elevating basal levels of NFκB-activity, but also similar capacities in profoundly
inhibiting TNF-induced NFκB-activity. Further, the loss of SH3BP4-binding ability
neither showed any effect on TNF-stimulated apoptosis, since both- wildtype
MCF159 and its AxxA variant potently inhibited proteolytic caspase-8 and -3
cleavage. Conclusively, at this point, the selective binding of MC159 to SH3BP4
evolved seemingly to support inhibition of autophagy.
In addition to the already mentioned functions of SH3BP4 [93-95], more recent
findings support the importance of this protein in various additional cell
signalling pathways. Just lately, Antas et al. reported that SH3BP4 negatively
regulates Wnt-signaling by modulating the nuclear localization of β-catenin.
Thereby SH3BP4 functions as tumour-suppressor in intestinal stem cells [97].
Another study from Luo et al. further links SH3BP4 to amino acid regulated
mTORC1-signaling. The authors state that upon amino acid starvation of cow
mammary gland epithelial cells (CMECs), sestrin2 (SESN2) is expressed and binds
to SH3BP4, what leads to negative regulation of mTORC1 as described by Kim et
al. [95] and subsequently to reduced synthesis of casein [155].
Interestingly, SH3BP4 has also been reported to be part of a multiprotein
complex, called “LIFT” which is thought to regulate endosome positioning and -
intracellular movement by remodelling of actin [96]. Myosin VI is a key
component of this complex and is also known to bind selective autophagy
receptors, and by its action, as “actin-based motor” it helps to deliver the bound
receptor-cargo complexes to the growing phagophore [106]. Whether the LIFT-
complex, and thereby SH3BP4 and a putatively bound MC159, could also directly
be involved in this process would surely be of interest for further investigations.
Apart from this, SH3BP4 increasingly gains importance as a biomarker in
different cancer types, such as laryngeal and metastatic prostate cancer [156,
157].
These novel findings add not only to the understanding of SH3BP4-biology but
also highlight the functional diversity of this protein. Our finding of MCV MC159
specifically targeting SH3BP4 to support its inhibitory effect on cellular
autophagy adds yet another piece to the picture, which outlines the complex role
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of SH3BP4 in the cell. Further investigations addressing the question of whether
MC159-SH3BP4 interaction also affects other functions of SH3BP4 will be of
great interest. Preliminary work of our laboratory on the alteration of TfR1-
internalization by binding of MC159 to SH3BP4 showed an effect in transferrin-
uptake assays. However, a direct correlation of this effect with SH3BP4-binding
capacity of MC159 could not be shown, suggesting an indirect function of MC159
underlying this observation (C.Schmotz, unpublished data).
In summary, the results of study III clearly support the hypothesis that
recruitment of SH3BP4 by MC159 N-terminal SH3-binding motif actively
contributes to its ability to suppress autophagy. MCV establishes persisting
infections which can last for years. For this purpose, the virus has developed
complex strategies which make it highly adapted to its host cells, human
keratinocytes, and almost invisible to the host’s immune system. The
suppression of host cellular autophagy is knowingly one of these strategies and
is typically employed by large DNA-viruses establishing long-lasting infections
[112].
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6. Conclusions
“As the elucidation of the structure of the DNA double helix was to the molecular 
biology, so the discovery of modular binding domains was important in 
reorienting and focusing ideas in the signalling and opening the door to new 
experimental approaches” [5]. This statement by Professor Bruce Mayer, who is 
one of the pioneers in the field of modular protein domains, emphasises the 
fundamental role of modular domains in cellular signalling. SH3 domains 
represent the archetype and most abundant group of protein modular binding 
domains. The human genome encodes for more than 300 different SH3 domains, 
expressed in 220 proteins, demonstrating their absolute necessity for the cell.
In general, SH3 domain-mediated interactions are considered to exhibit rather 
moderate affinities, mostly because of their participation in transient protein 
complex assemblies. By reporting the discovery of numerous novel, high-affinity 
SH3 domain-mediated interactions, we illustrate another, commonly rarely 
appreciated feature of this vital protein networking module. Moreover, the 
presented findings clearly support phage-affinity screen technology as a bona 
fide method for the identification of such strong and selective SH3 domain 
interactions. By direct comparison of results we obtained from phage-
screenings, peptide-arrays and semi-quantitative pull-down assays, we can 
conclude that a critical aspect in high affinity and high selectivity of SH3 domain 
interactions is the existence of additional contacts between the ligand-protein 
and the preferred SH3 domain. Despite our finding that this type of high-affinity 
SH3-mediated interaction is rather the exception than the rule in the human SH3 
interactome, the novel interactions we identified, are a valuable resource for 
future investigations addressing functional consequences or structural features.
The relevance and impact of highly affine and selective SH3 domain-mediated 
interactions becomes further evident in the context of host-cell signalling 
exploration by pathogens, especially viruses. Our findings shed light into how IAV 
NS1 hijacks and manipulates host PI3K signalling by establishing a strong 
interaction with cellular Crk adaptor proteins and thereby forcing the 
reorganization of existing host cellular protein interactions. The findings prove 
how powerful NS1 interferes with elements of host cellular signalling, by 
adoption, incorporation and probably further improvement of an SH3 binding 
motif. Nevertheless, we still lack an answer to the question, how IAV benefits 
from hyper-activation of PI3K signalling by Crk(L)-binding competent NS1 
proteins. The interplay of the host cell- and IAV strain origin clearly plays a 
significant role in this context. However, future work on this topic is required to 
answer this question fully.
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Of no less significance is the finding of MCV MC159 protein recruiting SH3BP4 via
an SH3-mediated interaction and the discovery that this viral FLIP depends on
binding to host cell SH3BP4-SH3 domain to inhibit the cellular autophagy
machinery efficiently. Our findings add thereby essential pieces to the big puzzle
of understanding, how this virus escapes the human immune defence almost
completely. However, there is undoubtedly still a lot to learn about this
multifunctional key factor of MCV immune evasion and its actions. The
elucidation of the mechanism behind autophagy inhibition, supported by MC159
binding to SH3BP4, to begin with.
In conclusion, the presented results provide an outline of the presence and
frequency of high affinity and selective SH3-mediated interactions in the human
SH3 interactome. In that context, we identified strong and selective SH3 partners
for 19 potential SH3-ligand proteins and thereby provided a useful platform for
future investigations. The results we present on the reorganization of the Crk(L)-
PI3K-signalling complex by SH3-binding competent IAV NS1 proteins, underline
the consequences such high affinity and selective SH3-mediated interactions can
have on host cell protein complex formation and signalling when hijacked by
pathogens. The data we present on MCV MC159 protein binding to host cell
SH3BP4, introduces a new member into the group of viral SH3 ligands. Moreover,
by identifying this interaction as an essential feature of MC159 for its efficient
suppression of cellular autophagy, we introduce another example how such
highly selective and strong interactions of viral SH3 domain ligands with their
target SH3 domain can manipulate host cell signalling.
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